| Abderrazek F, Chakroun T, Addad F, Dridi Z, Gerotziafas G, Gamra H, et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 2010;125:e265–8 | D |
| Abuzahra M, Pillai M, Caldera A, Hartley WB, Gonzalez R, Bobek J, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Am J Cardiol 2008;102:401–3 | C |
| Ahmed N, Meek J, Davies GJ. Plasma salicylate level and aspirin resistance in survivors of myocardial infarction. J Thromb Thrombolysis 2010;29:416–20 | D |
| Ahn SG, Lee SH, Sung JK, Kim JY, Yoon J. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. Platelets 2011;22:305–7 | C |
| Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385–90 | A |
| Aleil B, Jacquemin L, De PF, Zaehringer M, Collet JP, Montalescot G, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008;1:631–8 | C |
| Aleil B, Meyer N, Cazenave JP, Mossard JM, Gachet C. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005;94:886–7 | C, D |
| Alessi M-C, Cuisset T, Quilici J, Cohen W, Fourcade L, Grosdidier C, et al. Benefit of tailored therapy with high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel non responders undergoing coronary stenting for ACS. J Thromb Haemost 2011;9:48 | D |
| Alessi M-C, Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, et al. High post-treatment platelet reactivity and impaired clinical prognosis but adequate response to thienopyridine in elderly patients with unstable coronary disease. J Thromb Haemost 2011;9:791 | B, C |
| Alexander W, Price MJ, Mega JL. Platelet reactivity: The GRAVITAS trial. P T 2011;36:47 | B, C |
| Alexopoulos D, Plakomyti T-E, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. Int J Cardiol 2012;154:333–4 | A |
| Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? J Am Coll Cardiol 2006;48:1751–4 | A |
| Almsherqi ZA, McLachlan CS, Sharef SM. More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized cross-over trial. J Thromb Haemost 2006;4:1638–9 | A |
| Althoff TF, Fischer M, Knebel F, Langer E, Ziemer S, Baumann G. Elevated residual platelet reactivity to adenosine diphosphate and arachidonic acid in patients after myocardial infarction compared to patients after elective coronary stenting. Eur Heart J 2009;30:330 | D |
| Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2004;2:1–8 | A |
| Ambrus JL, Ambrus CM, Akhter S. Aspirin ‘allergy’ and resistance. J Am Coll Cardiol 2004;44:939–40 | A |
| Anand SS. Vascular viewpoint. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002;105:1650–5 | A |
| Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37–42 | D |
| Andreassi MG, Adlerstein D, Coceani M, Shehi E, Vecoli C, Sampietro T, et al. High-risk single-nucleotide polymorphisms (SNPs) and genetic score on recurrent cardiovascular events following ischaemic heart disease. Eur Heart J 2011;32:947 | B, C |
| Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007;98:707–9 | A |
| Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541–7 | C |
| Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265–74 | C |
| Angiolillo DJ. Applying platelet function testing in clinical practice: What are the unmet needs? JAMA 2011;306:1260–1 | A |
| Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer? J Thromb Haemost 2006;4:2563–5 | A |
| Ankolekar S, Fox S, May J, Bath P. Assessing the efficacy of antiplatelet agents using remote testing of platelet P-selectin: preliminary observations from the triple antiplatelets for reducing dependency after ischaemic stroke (TARDIS) platelet sub study. Platelets 2010;21:395 | D |
| Ann S-G, Lee S-H, Sung JK, Lee J-W, Youn Y-J, Kim J-Y, et al. High post-clopidogrel platelet reactivity assessed by VerifyNow P2Y12 assay doses not predict stent thrombosis in acute coronary syndromes. J Am Coll Cardiol 2011;57(Suppl. 1):E929 | C |
| Anon. A mainstay drug underperforms. But a bedside test makes it easier to spot ‘aspirin resistance’. Heart Advisor 2004;7:3 | A |
| Anon. Aspirin resistance studied. US Pharm 1995;20:98 | A |
| Anon. Aspirin resistance: a worry? Johns Hopkins Medical Letter: Health After 50 2005;16:1–2 | A |
| Anon. I’ve been taking aspirin daily for 25 years, and clopidogrel for several years. In spite of this, I’ve had a number of heart attacks. You reported recently on people who can’t benefit from aspirin, and I think I may be one of them. What should I do? Heart Advisor 2004;7:8 | A |
| Anon. The importance of ‘aspirin resistance’. Aust J Pharm 2009;90:77 | A |
| Antoniucci D. Editorial comment: No role for triple antiplatelet therapy? J Am Coll Cardiol 2011;57:290–1 | A |
| Aradf D, Rideg O, Vorobcsuk A, Horvath IG, Komocsi A. Impact of cytochrome P450 2C19 and ABCB1 genotypes on post-clopidogrel platelet reactivity and clinical outcome. J Am Coll Cardiol 2010;56(Suppl. 1):B1–2 | C |
| Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543–51 | B, C |
| Aradi D, Komocsi A. Platelet function monitoring in patients on clopidogrel: what should we learn from GRAVITAS? Platelets 2012;23:167–76 | A |
| Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Konyi A, et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012;42:384–92 | C |
| Aradi D, Tokes-Fuzesi M, Paska T, Komocsi A. Monitoring the efficacy of antiplatelet therapy: all methods are equal, but some methods are more equal than others? Am Heart J 2008;155:e33 | A |
| Aradi D, Vorobcsuk A, Pinter T, Konyi A, Magyari B, Horvath IG, et al. Doubling the maintenance dose of clopidogrel in patients with high post-clopidogrel platelet reactivity after percutaneous coronary intervention: the DOSER randomized, placebo-controlled trial. Eur Heart J 2010;31:970 | B, C |
| Arai T, Endo A, Ikeda Y, Matsubara Y, Ogawa S, Ohono Y, et al. Impact of chronic kidney disease on platelet reactivity in patients with drug-eluting stent implantation. Catheter Cardiovasc Interv 2009;73:S77 | C, D |
| Araullo MLC. Aspirin resistance among patients with recurrent non-cardioembolic stroke detected by rapid platelet function analyzer. J Stroke Cerebrovasc Dis 2008;17:2–8 | D |
| Arazi HC, Doiny DG, Torcivia RS, Grancelli H, Waldman SV, Nojek C, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact Cardiovasc Thorac Surg 2010;10:863–7 | D |
| Ari H, Aradi D, Komocsi A, Price MJ, Cuisset T, Hazarbasanov D, et al. Efficacy and safety of platelet function-guided antiplatelet therapy: systematic review and meta-analysis. Int J Cardiol 2012;155:S49–50 | C |
| Artang R, Jensen E, Pedersen F, Frandsen NJ. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000;97:499–503 | D |
| Ashbrook M, Schwatz J, Heroux A, Escalante V, Jeske W, Walenga J, et al. Platelet function in patients with a left ventricular assist device. J Thromb Haemost 2011;9:344 | D |
| Awidi A, Saleh A, Dweik M, Kailani B, Abu-Fara M, Nabulsi R, et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels 2011;26:516–22. [Erratum published in Heart Vessels 2011;26:523] | D |
| Aydinalp A, Atar I, Altin C, Gulmez O, Atar A, Acikel S, et al. Platelet function analysis with two different doses of aspirin. Turk Kardiyol Dernegi Ars 2010;38:239–43 | D |
| Aydinalp A, Atar I, Gulmez O, Atar A, Acikel S, Bozbas H, et al. The clinical significance of aspirin resistance in patients with chest pain. Clin Cardiol 2010;33:E1–7 | D |
| Bach R, Jung F, Kohsiek I, Ozbek C, Spitzer S, Scheller B, et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thromb Res 1994;74(Suppl. 1):55–67 | D |
| Balduini CL, Noris P, Bertolino G, Previtali M. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1993;69:522–3 | D |
| Baluda VP, Lakin KM, Pabvlishchuk SA, Deianov I, Nedelkovskii I. [Aspirin sensitivity of healthy persons and patients.] Kardiologiia 1981;21:55–7 | C, D |
| Banti A, Mosialos L, Zarifis J, Kaprinis I, Vassara C, Kiskinis D, et al. Pharmacological resistance to clopidogrel (PRC) status is modified in time after percutaneous coronary intervention. A prospective study with repeated point of care monitoring with multiplate analyser. J Thromb Haemost 2009;7:587 | C |
| Barbano G, Solera L. [On the control of anticoagulant therapy in myocardial infarct. Thromboelastography and quick’s time: considerations and comparisons.] Minerva Med 1964;55:612–18 | B |
| Barkagan ZS, Chernenko VF. [The significance of thromboelastography in obliterating diseases of the arteries of the extremities.] Khirurgiia (Mosk) 1969;45:60–5 | B |
| Barragan P, Paganelli F, Camoin-Jau L, Bourguet N, Boulay-Moine D, Moulard M, et al. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010;104:410–11 | C |
| Basili S, Pignatelli P, Carnevale R, Di SS, Loffredo L, Violi F. PFA-100 A reliable tool to evaluate patients compliance to aspirin therapy. J Thromb Haemost 2009;7:883 | D |
| Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation 2005;111:e267–71 | A |
| Beard K, Folia C, Liovas A. Platelet function tests are highly variable when used to identify patients resistant to clopidogrel. Value Health 2010;13:A342 | B, C |
| Beer JH. Aspirin resistance for clinicians. Curr Hematol Rep 2004;3:149–50 | A |
| Behr T, Kuch B, Behr W, von Scheidt W. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 2011;100:907–14 | C |
| Beigel R, Herscovici R, Fefer P, Hod H, Matetzky S. The anti-platelet effect of prasugrel as compared with clopidogrel in ST-elevation acute myocardial infarction patients undergoing primary angioplasty. J Am Coll Cardiol 2012;59(Suppl. 1):E480 | C |
| Berent R, Sinzinger H. ‘Aspirin – resistance’? A few critical considerations on definition, terminology, diagnosis, clinical value, natural course of atherosclerotic disease, and therapeutic consequences. Vasa 2011;40:429–38 | A |
| Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 2009;48:258–61 | C |
| Berger PB. Resistance to antiplatelet drugs: is it real or relevant? Catheter Cardiovasc Interv 2004;62:43–5 | A |
| Berglund U, Wallentin L. Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris. Adv Prostaglandin Thromboxane Leukot Res 1985;13:277–80 | D |
| Berkowitz SD, Frelinger AL, III, Hillman RS. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998;136:S51–65 | A |
| Bernal ME, Saban RJ. [Aspirin resistance.] Med Clin 2005;124:30–6 | A |
| Bernlochner I, Byrne RA, Kastrati A, Sibbing D. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Exp Rev Cardiovasc Ther 2011;9:999–1014 | A |
| Bertrand OF, Rodes-Cabau J, Rinfret S, Larose E, Bagur R, Proulx G, et al. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am J Cardiol 2009;104:1235–40 | C |
| Bezborod’ko BN, Batrak AA. [Thromboelastographic study of whole blood and oxalate plasma in patients with coronary arteriosclerosis in the ischemic stage.] Ter Arkh 1971;43:53–5 | C |
| Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004;43:1127–9 | A |
| Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU, et al. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels 2006;21:102–7 | C |
| Biondi-Zoccai G, Lotrionte M. Aspirin resistance in cardiovascular disease. BMJ 2008;336:166–7 | A |
| Bisdas T, Haverich A, Teebken OE. Letter by Bisdas, et al. regarding article, ‘Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial’. Circulation 2011;124:e194–6 | A |
| Blatt PM, Roberts HR. Letter: Platelet-function tests: predictive value. New Engl J Med 1975;293:611 | A |
| Bochenek T, Wilczynski M, Wita K, Lelek M, Trusz-Gluza M, Bochenek A. [Evaluation of platelet response to antiplatelet drugs. An important clue for cardiologists and cardiosurgeons.] Kardiol Pol 2007;65:1266–9 | A |
| Bocks M, Majahalme N, Russell M. Aspirin non-responsiveness, genetic polymorphisms in platelet aggregation, and the risk of thrombus formation in children with congenital heart disease. Catheter Cardiovasc Interv 2010;76:S14–15 | B |
| Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5–10 | C |
| Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–11 | C |
| Bonello L, Camoin-Jau L, Dignat-George F, Paganelli F. A threshold of platelet reactivity for ischaemic events? Eur Heart J 2008;29:2185–6 | A |
| Bonello L, Harouri K, Sabatier F, Camoin-Jau L, Arnaud L, Baumstarck-Barrau K, et al. Level of ADP receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by CEC measurement. Eur Heart J 2010;31:976 | B, C |
| Bonello L, Lemesle G, De Labriolle A, Roy P, Steinberg DH, Pinto Slottow TL, et al. Impact of a 600 mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;102:1318–22 | C |
| Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630–6 | C |
| Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467–73 | C |
| Bonten T, Snoep JD, Assendelft WJ, van der Meer V, Zwaginga JJ, Rosendaal FR, et al. Aspirin am or pm? A randomized cross-over trial. J Thromb Haemost 2011;9:334–5 | A |
| Boos CJ, Lip GY. Platelet activation and cardiovascular outcomes in acute coronary syndromes. J Thromb Haemost 2006;4:2542–3 | A |
| Bouman HJ, Breet NJ, Van Werkum JW, Zwart B, Ten CH, Hackeng CM, et al. Platelet reactivity in patients with coronary stent thrombosis. Eur Heart J 2010;31:973 | D |
| Bouman HJ, van Werkum JW, Breet NJ, Ten CH, Hackeng CM, ten Berg JM. A case–control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011;9:909–16 | D |
| Bradbury J. Aspirin resistance may increase death risk in some patients with heart disease. Lancet 2002;359:1128 | A |
| Brar S, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim H-S, et al. Impact of clopidogrel on-treatment platelet reactivity on stent thrombosis after percutaneous coronary intervention: results from a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;57(Suppl. 1):E1632 | C |
| Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945–54 | C |
| Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al. Antiplatelet therapy and platelet function testing. Clin Cardiol 2008;31(Suppl. 1):I36. [Erratum published in Clin Cardiol 2009;32:111] | A |
| Breet NJ, Bouman HJ, van Werkum JW, Ruven H, Hackeng CM, Berg JMT. First prospective comparison between platelet function tests in prediction of clinical outcome in 1100 patients undergoing coronary stent placement: Do point-of-care platelet function assays predict clinical outcomes in clopidogrel pretreated patients undergoing elective PCI (POPular study). Circulation 2010;120:2153 | C |
| Breet NJ, De Jong C, Bos WJW, van Werkum JW, Bouman HJ, Kelder JC, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Eur Heart J 2011;32:187 | C |
| Breet NJ, Pittens CAC, Bouman HJ, van Werkum JW, ten Berg JM, Hackeng CM. The effect of platelet reactivity on infarct related artery patency in patients with ST-elevation myocardial infarction. J Thromb Haemost 2009;7:590 | C |
| Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Hackeng CM, ten Berg JM. The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction. Thromb Haemost 2011;106:331–6 | D |
| Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–62. [Errata published in JAMA 2010;303:1257, JAMA 2011;305:2174, JAMA 2011;305:2172–3] | C |
| Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention. J Thromb Haemost 2010;8:2326–8 | C |
| Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, ten Berg JM, Hackeng CM. Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events. Thromb Haemost 2011;105:197–9 | C |
| Breet NJ. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2011;305:2174 | C |
| Briongos FS, Salido-Tahoces L, de Juan-Baguda J, Marti-Sanchez D. [Multiple arterial thrombosis and resistance to conventional antiaggregation.] Rev Esp Cardiol 2011;64:836–7 | A |
| Brister SJ, Buchanan MR. Aspirin ‘resistance’ and its impact on cardiovascular morbidity and mortality: it is real, clinically relevant and should be measured. Heart 2009;95:1223–4 | A |
| Brizzio M, Shaw R, Sperling J, Grau J, Zapolanski A. Low responsiveness to clopidogrel therapy as a possible predictor for early failure of coronary percutaneous intervention requiring surgical revascularization. Innov Technol Tech Cardiothorac Vasc Surg 2011;6:190 | B |
| Brizzio ME, Zapolanski A, Shaw RE, Collins M, Bosticco B, Sperling JS. The utilization of platelet inhibition tests in patients who receive preoperative clopidogrel reduces the waiting time for elective coronary surgery. Innov Technol Tech Cardiothorac Vasc Surg 2010;5:193 | B |
| Broussalis E, Killer-Oberpfalzer M. Is multiple electrode platelet aggregometry beneficial in the management of carotid artery stenting? Intervent Neuroradiol 2011;17:210 | B, C |
| Buchanan MR. Acetylsalicylic acid resistance and clinical outcome – the Hobikoglu study is worth noting. Can J Cardiol 2007;23:207–8 | A |
| Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O. Aspirin non-responder status and early neurological deterioration: a prospective study. Clin Neurol Neurosurg 2011;113:196–201 | D |
| Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312–17 | C |
| Cairns JA, Eikelboom J. The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy. J Am Coll Cardiol 2008;52:1978–80 | A |
| Calviere L, Voisin S, Coulon G, Viguier A, Sie P, Larrue V. Prevalence of low responsiveness to clopidogrel in patients with stroke or TIA. Cerebrovasc Dis 2011;31:259 | D |
| Camilleri E, Jacquin L, Paganelli F, Bonello L. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr Cardiol Rep 2011;13:296–302 | A |
| Camoin-Jau L, Bonello L, Armero S, Com O, Barragan P, Paganelli F, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. J Thromb Haemost 2009;7:589 | C |
| Campo G, Ferraresi P, Marchesini J, Bernardi F, Valgimigli M. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemost 2011;9:2106–8 | C |
| Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474–83 | C |
| Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006;48:2178–85 | C |
| Can MM, Tanboga IH, Turkyilmaz E, Karabay CY, Akgun T, Koca F, et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res 2010;125:e132–7 | D |
| Cao J, Li XL, Fan L, Ye L. Single nucleotide polymorphisms of Ho-1 and Cox-1 are associated with complete aspirin resistance defined by light transmittance aggregation in the elderly. Heart 2011;97(Suppl. 3):A188 | D |
| Capanni M, Prisco D, Antonucci E, Chiarugi L, Boddi V, Abbate R, et al. The pre-procedural platelet state predicts clinical recurrence after coronary angioplasty. Int J Clin Lab Res 1999;29:145–9 | C |
| Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180–7 | D |
| Caron N, Rivard GE, Michon N, Morin F, Pilon D, Moutquin JM, et al. Low-dose ASA response using the PFA-100 in women with high-risk pregnancy. J Obstet Gynaecol Can 2009;31:1022–7 | B, D |
| Carrie D, Garcia C, Gratacap MP, Voisin S, Payrastre B, Sie P. Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation. J Thromb Haemost 2009;7:1411–13 | C, D |
| Casassus F, Leroux L, James C, Sidibe S, Desplantes A, Naibo D, et al. Response to prasugrel in ST elevation myocardial infarction patients: Is it as rapid as we expected? J Am Coll Cardiol 2011;58(Suppl. 1):B43–4 | B, C |
| Cassiano O, Mairano C. [Considerations and research on the relations between chronic peripheral arteriopathy and blood coagulation.] Minerva Cardioangiol 1963;11:510–15 | B |
| Cattaneo M. [Tailored treatment with clopidogrel based on the results of platelet function tests should not be implemented, in the absence of clear indications on the methodology to be used.] G Ital Cardiol 2011;12:172–3 | B, C |
| Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)? Eur Heart J 2007;28:1673–5 | A |
| Cayla G, Macia JC, Rabesandratana H, Roubille F, Gervasoni R, Pasquie JL, et al. Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch Cardiovasc Dis 2008;101:743–51 | C |
| Cepelakova H, Cepelak V, Sova J. [Prognostic significance of some coagulation changes in myocardial infarct.] Vnitr Lek 1973;19:478–86 | B |
| Chen H. Randomized comparison of adjunctive Naoxintong versus standard maintenance dose clopidogrel in patients with CYP2C19*2 gene mutation: results of the ABNJC-CYP2C19*2 (Adjunctive Buchang Naoxintong Jiaonang Versus Standard Maintenance Dose Clopidogrel in Patients with CYP2C19*2 Gene Mutation) randomized study. Int J Cardiol 2011;152:S26 | B, C |
| Chen L, Bracey AW, Radovancevic R, Cooper JR, Jr, Collard CD, Vaughn WK, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004;128:425–31 | C, D |
| Chen W-H, Lee P-Y, Ng W, Kwok JYY, Cheng X, Lee SWL, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary Intervention. Am J Cardiol 2005;96:760–3 | D |
| Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122–6 | D |
| Chen W-H, Lee P-Y. Reply to ‘comments in response to low-dose aspirin increases aspirin resistance in patients with coronary artery disease’. Am J Med 2006;119:287–8 | A |
| Chen YW, Lee KY, Li CH, Lin YY, Yang CD, Hsieh CF, et al. Difference in platelet function test could predict prognosis in the acute stage of ischemic stroke. Cerebrovasc Dis 2011;31:281–2 | D |
| Chen ZQ. Influence of Ranitidine on gastrointestinal hemorrhage and thrombosis caused by dual antiplatelet therapy after PCI in patients with coronary heart disease. Cardiology 2010;117:48–9 | C |
| Chiesa FT. [Thromboelastography in coronary heart disease: evaluations provided of the blood coagulation situation; indications for therapy.] G Gerontol 1971;19:800–4 | B |
| Choi DH, Suh JW, Park KW, Kang HJ, Kim HS. Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients. Clin Ther 2009;31:1804–11 | B, C |
| Cholette JM, Mamikonian L, Alfieris GM, Blumberg N, Lerner NB. Aspirin resistance following pediatric cardiac surgery. Thromb Res 2010;126:200–6 | B |
| Chooi JL, Vesamia SA, Gama CA, Szecowka-Harte SR, Brown V. Thromboelastography in prediction of blood loss after cardiac surgery. Eur J Anaesthesiol 2011;28:84 | D |
| Chow SL, Cheung RJ. Aspirin resistance: a growing concern. Formulary 2006;41:192–201 | A |
| Christiaens L, Allal J, Brizard A, Macchi L. Aspirin resistance: a reality? Med Ther 2003;9:181–6 | A |
| Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010;8:148–56 | B, C, D |
| Clappers N, van Oijen MG, Sundaresan S, Brouwer MA, Te Morsche RH, Keuper W, et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008;100:70–5 | C |
| Cocozza M, Milani M, Picano T, Oliviero U, Russo N, Coto V. Antiaggregatory effects of picotamide in long-term treatment: a 2-year, double-blind placebo-controlled trial. Vasc Med 1997;2:292–5 | B |
| Cohen AH, Doiny D, Waldman SV, Spampinato TR, Grancelli H, Miriuka S, et al. Association between reduced aspirin inhibition and platelet turnover in cardiac surgery. Eur Heart J 2009;30:916–17 | D |
| Cohen M, Merino A, Hawkins L, Greenberg S, Fuster V. Clinical and angiographic characteristics and outcome of patients with rest-unstable angina occurring during regular aspirin use. J Am Coll Cardiol 1991;18:1458–62 | C |
| Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011;161:5–12 | A |
| Collet J-P, Hulot JS, Pena ANA, Vilard ERIC, Esteve JB, Cayla G, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: impact on clinical events and on. Eur Heart J 2009;30:906 | B, C |
| Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923–33 | C |
| Conti CR. Is aspirin resistance a risk factor? Clin Cardiol 2005;28:163–4 | A |
| Cordina SM, Vazquez G, Suri MF, Lakhsminarayan K, Qureshi Z. Does aspirin failure increase the chances of recurrent stroke and/or death among patients with ischemic stroke: a pooled analysis of two prospective trials. Stroke 2010;41:e214 | C |
| Cotton JM, Worrall AM, Hobson AR, Smallwood A, Amoah V, Dunmore S, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? Cardiovasc Ther 2010;28:139–46. [Erratum published in Cardiovasc Ther 2010;28:254. Rajendra R (corrected to Raghuraman RP)] | C |
| Cowley MJ, Kuritzky L. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Curr Med Res Opin 2009;25:1477–90 | C |
| Cox D. Aspirin resistance: a nebulous concept. J Clin Pharmacol Pharm 2010;1:39–47 | A |
| Crescente M, Di Castelnuovo A, Iacoviello L, De Gaetano G, Cerletti C. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008;99:1129–31 | A |
| Cubero JM. Candy study: minor myocardial damage in patients with type 2 diabetes mellitus and dual hypo-responsiveness to aspirin and clopidogrel with Xience V stent implantation. J Am Coll Cardiol 2012;59(Suppl. 1):E488 | D |
| Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009;104:1078–82 | C |
| Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008;1:649–53 | C |
| Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600 mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006;48:1339–45 | C |
| Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007;97:282–7 | C |
| Cuisset T, Frere C, Quilici J, Poyet R, Bali L, Morange PE, et al. Glycoprotein IIbIIIa inhibitors improve clinical outcome after coronary stenting in clopidogrel non responders: a prospective, randomized study. Arch Cardiovasc Dis Suppl 2010;2:13 | C |
| Cuisset T, Hamilos M, Sarma J, Sarno G, Wyffels E, Vanderheyden M, et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008;101:1700–3 | D |
| Cuisset T, Morange P-E, Alessi M-C. High residual platelet reactivity and thrombotic events. JAMA 2011;306:2561 | A, B, C |
| Cuisset T, Quilici J, Fugon L, Cohen W, Roux P, Gaborit B, et al. Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. Arch Cardiovasc Dis 2011;104:306–12 | D |
| Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, Pankert M, et al. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 years versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Am J Cardiol 2011;108:1411–16 | C |
| Curzen N, Sambu N. Interventional cardiology: Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? Heart 2011;97:1433–40 | A |
| Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg 2009;108:734–42 | B, C |
| Dalal AR, D’Souza S, Shulman MS. Brief review: coronary drug-eluting stents and anesthesia. Can J Anaesth 2006;53:1230–43 | C |
| Dalal JJ, Bloom A, Henderson AH. Transmyocardial platelet behavior in CAD. Circulation 1981;63:969–70 | B, C, D |
| Dalal JJ, Penny WJ, Saunders KC, Sheridan DJ, Bloom AL, Henderson AH. Platelet counts and aggregates in coronary artery disease. Eur Heart J 1982;3:107–13 | C, D |
| Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980;99:746–52 | C |
| Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am J Med 2007;120:1–4 | A |
| Dalen JE. Is aspirin resistance due to noncompliance? Arch Intern Med 2008;168:550 | A |
| Dalen M, Van Der Linden J, Lindvall G, Ivert T. Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. Scand Cardiovasc J 2012;46:32–8 | D |
| D’Andrea D, Furbatto F, Boccalatte M, Scarpelli M. Use of point-of-care testing to assess optimal antiplatelet therapy when a nasogastric tube is the only way of administration. Int J Cardiol 2011;147:S67 | D |
| Darcy MD, Kanterman RY, Kleinhoffer MA, Vesely TM, Picus D, Hicks ME, et al. Evaluation of coagulation tests as predictors of angiographic bleeding complications. Radiology 1996;198:741–4. | C |
| Davlouros PA, Arseniou A, Hahalis G, Chiladakis J, Mazarakis A, Damelou A, et al. Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: a comparison of two strategies. Am Heart J 2009;158:585–91 | C |
| Dawson J, Quinn TJ, Rafferty M, Ray G, Walters MR, Lees KR. Aspirin resistance in patients with recent stroke: a case–control study. Cerebrovasc Dis 2009;27:45 | D |
| De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003;1:2048–50 | A |
| De Gaetano G. Aspirin resistance in diabetic patients. Diabetes Care 2004;27:1244–5 | A |
| De Matteis F, Barbano G. [The thrombelastogram in coronary disease.] Minerva Med 1963;54:194–202 | B, D |
| de Miguel CA, Cuellas RC, Diego NA, Samaniego LB, Alonso RD, Fernandez VF, et al. Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. Rev Esp Cardiol 2009;62:126–35 | C |
| de Miguel Castro A, Diego Nieto A, Perez de Prado A. Letter by de Miguel Castro, et al. regarding article, ‘cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up’. Circulation 2009;120:e98 | A |
| De Miguel Castro A, Nieto AD, Perez de Prado A. Letter by De Miguel Castro, et al. regarding article, ‘Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial’. Circulation 2012;125:e570 | A |
| De Rosa R, Galasso G, Piscione F, Santulli G, Iaccarino G, Piccolo R, et al. Increased risk of cardiovascular events associated with the GPIIIA PlA2 polymorphism. Cardiovasc Res 2010;87:S74–5 | C |
| Dekhtiar’ AL, Synovets AS. [Thromboelastogram data in patients with thromboobliterating diseases of the vessels.] Vrach Delo 1967;5:45–7 | C, D |
| Deliargyris EN, Boudoulas H. Aspirin resistance. Hell J Cardiol 2004;45:1–5 | A |
| Dengler R, Lichtinghagen R, Schumacher H, Weissenborn K, Worthmann H. C-reactive protein and its pharmacologic reduction as predictor of outcome in the early treatment with aspirin and extended-release dipyridamole versus low dose aspirin alone for TIA/ischemic stroke within 24 hour of symptom-onset (EARLY-Trial). Stroke 2010;41:e261 | C |
| D’Erasmo E, Aliberti G, Celi FS, Vecci E, Mazzuoli G. [Sequential evaluation of platelet count and mean platelet volume during myocardial infarction.] Medicina 1988;8:58–60 | B, D |
| D’Erasmo E, Aliberti G, Celi FS, Vecci E, Romagnoli E, Mazzuoli G. [Changes in several blood platelet parameters in cerebral infarct.] Recenti Prog Med 1988;79:12–14 | B, C, D |
| D’Erasmo E. [Relationship between number and volume of circulating blood platelets in cerebral and myocardial infarct.] Recenti Prog Med 1990;81:675–6 | A, C, D |
| Dhatariya KK. Aspirin for everyone over 50? Don’t forget aspirin resistance. BMJ 2005;331:161 | A |
| Di Giovanni V, Agrifoglio G. [Thrombelastographic observations in the postoperative period and its value in the prevention of thrombophletitic complications.] Minerva Chir 1963;18:299–311 | B, D |
| Di Minno G, Violi F. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 2004;113:97–9 | A |
| Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010;56:550–7 | C |
| Dietrich GV, Schueck R, Menges T, Kiesenbauer NP, Fruehauf AC, Marquardt I. Comparison of four methods for the determination of platelet function in whole blood in cardiac surgery. Thromb Res 1998;89:295–301 | B, D |
| Dmoszynska-Giannopoulou A, Pluta A, Kowalewski J. [Platelet function and lipid disorders in diabetics.] Pol Arch Med Wewn 1979;62:293–7 | B, D |
| Dmoszynska-Giannopoulou A. [Function and coagulative activity of blood platelets in patients with attacks of transient cerebral ischemia.] Polski Tygodnik Lekarski 1984;39:1569–71 | B, D |
| Doraiswamy VA. Letter by Doraiswamy regarding article, ‘Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study’. Circulation 2010;121:e235 | A |
| Drouet L, Bal dit SC, Henry P. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients.] Drugs 2010;70(Suppl 1.):9–14 | A |
| Drouet L. [Is aspirin resistance a reality?] Rev Med Interne 2004;25:101–3 | A |
| Drzewoski J, Watala C. Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care 2004;27:1245–6 | D |
| d’Udekem Y. The devastating consequences of thrombosis of systemico pulmonary shunts and the blind administration of aspirin. Thromb Res 2010;126:163 | A |
| Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R. Comparison of a rapid platelet function assay – Verify Now Aspirin – with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb Res 2007;120:485–8 | B, D |
| Eikelboom J, Oldgren J, Reilly P, Yusuf S, Wallentin L, Ezekowitz M, et al. No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the rely trial. J Thromb Haemost 2011;9:346 | D |
| Eikelboom J. Aspirin resistance: does it exist and is it an important clinical problem? Clin Adv Haematol Oncol 2006;4:268–70 | A |
| Eikelboom JW, Emery J, Hankey GJ. The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke 2010;41:2398–9 | A |
| Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 2003;41:966–8 | A |
| El Ghannudi S, Ohlmann P, Jesel L, Radulescu B, El Adraa E, Crimizade U, et al. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011;217:465–72 | C |
| El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC Cardiovasc Interv 2010;3:648–56 | C |
| El Ghannudi S, Ohlmann P, Wiesel ML, Radulescu B, Bareiss P, Chauvin M, et al. Impact of platelet poor responsiveness to clopidogrel on cardiovascular outcome in type 2 Diabetes mellitus patients treated by percutaneous coronary angioplasty. Eur Heart J 2009;30:194 | B, C |
| El Ghannudi S, Ohlmann P, Wiesel ML, Radulescu B, Bareiss P, Chauvin M, et al. Platelet reactivity assessed by flow cytometric VASP phosphorylation is an independent predictor of death and cardiovascular death in unselected patients undergoing PCI. Eur Heart J 2009;30:192–3 | B, C |
| Lu TQ, Mu DJ, Tang YD, Chen J, Yuan JQ, Wu YJ, et al. The clopidogrel response is associated with clinical outcomes of the CHD patients who underwent elective PCI. Cardiology 2010;117:58–9 | B |
| Elwood P, Morgan G. Aspirin resistance: what is the risk of cardiovascular morbidity? BMJ 2008;336:291 | A |
| Elwood PC, Beswick A, Pickering J, McCarron P, O’Brien JR, Renaud SR, et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. Br J Haematol 2001;113:514–20 | C |
| Elwood PC, Renaud S, Beswick AD, O’Brien JR, Sweetnam PM. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998;80:578–82 | B |
| Elwood PC, Renaud S, Sharp DS, Beswick AD, O’Brien JR, Yarnell JW. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38–44 | B |
| Eng M, Hudson PA, Endemann S, Barker C, Williams M, Levisay J, et al. Low on-treatment reactivity with clopidogrel does not significantly impact bleeding complications in patients receiving dual anti-platelet therapy. J Am Coll Cardiol 2011;57(Suppl. 1):E1635 | C |
| Epimakhova OV, Sumarokov AV. [Functional activity of thrombocytes in myocardial diseases.] Kardiologiia 1983;23:32–5 | B, C, D |
| Erlinge D, Berg JT, Foley D, Angiolillo D, Brown P, Wagner H, et al. Prasugrel 5 mg in low body weight patients reduces platelet reactivity to a similar extent as prasugrel 10 mg in higher body weight patients: results from the feather trial. J Am Coll Cardiol 2012;59(Suppl. 1):E341 | C |
| Esposito G. Responsiveness to P2Y12 receptor inhibitors. Curr Opin Cardiol 2011;26(Suppl. 1):S31–7 | A |
| Eto K, Ochiai M, Isshiki T, Takeshita S, Terakura M, Sato T, et al. Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction. Jpn Circ J 2001;65:279–82 | D |
| Ettinger MG. Thromboelastographic studies in cerebral infarction. Stroke 1974;5:350–4 | B, D |
| Lindhoff-Last E. Non-compliance and genetic polymorphisms: when patients do not respond to ASA or clopidogrel. Dtsch Apoth Ztg 2010;150:59–60 | A |
| Fang H. The effect of CYP2C19*17 on platelet response and clinical outcomes in patients taking clopidogrel: a meta-analysis. Ther Drug Monit 2011;33:479 | C |
| Faraday N, Braunstein JB, Heldman AW, Bolton ED, Chiles KA, Gerstenblith G, et al. Prospective evaluation of the relationship between platelet–leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 2004;15:9–14 | D |
| Farsad F, Safara E, Bakhshandeh H, Golpira R, Zavarehee A, Hashemian F. Assessment of clopidogrel resistance by platelet function test: optical aggregometry in ischemic heart disease patients undergoing coronary intervention. J Am Pharm Assoc 2011;51:218 | B, C |
| Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003;90:692–3 | B, D |
| Fefer P, Beigel R, Shenkman B, Gannot S, Varon D, Savion N, et al. Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. J Am Coll Cardiol 2012;59(Suppl. 1):E484 | B, C, D |
| Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2010;2:171–86 | A |
| Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 2006;23:559–67 | D |
| Feher G, Pusch G, Szapary L. Optical aggregometry and aspirin resistance. Acta Neurol Scand 2009;119:139 | A |
| Ferraris VA, Ferraris SP, Joseph O, Wehner P, Mentzer RM, Jr. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg 2002;235:820–7 | D |
| Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010;103:1128–35 | A |
| Fisher M, Johns T. Letter by Fisher and Johns regarding article, ‘Variable platelet response to aspirin and clopidogrel in atherothrombotic disease’. Circulation 2007;116:e521 | A |
| Fisher M, Knappertz V. Comments in response to ‘low-dose aspirin increases aspirin resistance in patients with coronary artery disease’. Am J Med 2006;119:287–8 | A |
| Fitscha P, Kaliman J, Sinzinger H, Peskar BA. Follow-up of in-vivo platelet function (platelet half-life, thromboxane B2) in patients with coronary heart disease. Vasa 1984;13:338–42 | D |
| Fitscha P, Sinzinger H. [Defects in the prostaglandin system. VII. (Generalized, inherited [?]) cyclooxygenase defect.] Wien Klin Wochenschr 1988;100:711–15 | A |
| FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003;361:542–4 | A |
| Focks JJ, van Oijen MG, Lanas A, Verheugt F, Brouwer MA. Co-administration of proton pump inhibitors and clopidogrel: a systematic review on laboratory and clinical endpoints. Gastroenterology 2011;140(Suppl. 1):S395 | B, C |
| Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2011;20:227–30 | D |
| Fontana P, Berdague P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 2010;8:2614–23 | D |
| Fontana P, Reber G, de Moerloose P. Assessing aspirin responsiveness using the Verify Now Aspirin assay. Thromb Res 2008;121:581–2 | B, C, D |
| Fontana P, Remones V, Reny JL, Aiach M, Gaussem P. P2Y1 gene polymorphism and ADP-induced platelet response. J Thromb Haemost 2005;3:2349–50 | B, C, D |
| Fontana P, Reny JL. Laboratory-defined aspirin resistance and recurrent cardiovascular events. Arch Intern Med 2008;168:549–50 | A |
| Foo F, Oldroyd KG. Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers Med 2011;5:9–30 | A |
| Forestier F, Belisle S, Contant C, Harel F, Janvier G, Hardy JF. [Reproducibility and interchangeability of the Thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery.] Can J Anaesth 2001;48:902–10 | D |
| Fosburgh D. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006;81:989 | A |
| Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation 2006;113:2865–7 | A |
| Frelinger AL, III, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol 2005;46:646–7 | A |
| Frelinger AL, III. Platelet reactivity with prolonged aspirin treatment – steady going at 2 year. Circ J 2010;74:1077–8 | A |
| Frelinger AL, III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Response to letter regarding article, ‘Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance’. Circulation 2007;115:e46 | A |
| Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009;7:1409–11 | B, C, D |
| Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838–43 | C |
| Frere C, Cuisset T, Quilici J, Gaborit B, Poyet R, Bali L, et al. Predictive ability of post treatment ADP-induced aggregation and VASP index on stent thrombosis after acute coronary syndrome in clopidogrel-treated patients: a prospective study. J Thromb Haemost 2009;7:585 | B, C |
| Freynhofer M, Brozovic I, Bruno V, Leherbauer L, Djurkovic M, Jarai R, et al. Routine determination of platelet reactivity in patients on long-term dual antiplatelet therapy: The WILMAA Registry. Eur Heart J Suppl 2010;12:F65 | C, D |
| Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, et al. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011;106:230–9 | C |
| Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003;326:82–3 | D |
| Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R. Monitoring the antiplatelet action of aspirin. JAAPA 1961;14:57–8 | B, D |
| Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Kuroda N, Ooyama M, et al. Effect of 450 mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. Heart Vessels 2010;25:182–6 | C |
| Gabriel SA, Beteli CB, Tanighuchi RS, Tristao CK, Gabriel EA, Job JR. Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc 2007;22:96–103 | A |
| Gaglia MA, Torguson R, Pakala R, Sardi G, Xue Z, Suddath WO, et al. Patients with acute coronary syndromes undergoing percutaneous coronary intervention have higher levels of on-treatment platelet reactivity. Circulation 2011;124(Suppl. 1):A9814 | C, D |
| Gaglia MA, Torguson R, Sardi G, Xue Z, Suddath WO, Kent KM, et al. Patients with acute coronary syndrome have higher levels of on-treatment platelet reactivity. J Am Coll Cardiol 2011;58(Suppl. 1):B48–9 | C, D |
| Gaglia MA, Torguson R, Xue Z, Pakala R, Gonzalez MA, Ben-Dor I, et al. Periprocedural myocardial infarction and high on-treatment platelet reactivity. J Am Coll Cardiol 2011;57(Suppl. 1):E1897 | C |
| Gajos GP, Undas A, Rostoff P, Nessler J, Piwowarska W. Responsiveness to clopidogrel after percutaneous coronary intervention can be improved with polyunsaturated omega-3 fatty acids especially in patients with CYP 2C19 loss-of-function polymorphism. Eur Heart J 2010;31:202 | D |
| Galvani M. High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis? J Thromb Haemost 2006;4:536–8 | A |
| Gao F, Wang ZX, Men JL, Ren J, Wei MX. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. Chin Med J 2011;124:1731–4 | D |
| Gao L, Li YJ, Chen KY. [Effects of supplementing qi and activating blood circulation method on platelet aggregation rate, adhesion rate and thromboxane B2 level in patients with stable angina pectoris and intolerable to aspirin.] Zhongguo Zhong Xi Yi Jie He Za Zhi 2008;28:300–3 | B |
| Garcia-Rinaldi R. Thromboprophylaxis with antiplatelet agents prevents cerebral thromboembolism in patients with mechanical aortic prostheses. Stroke 2011;42:e345 | B |
| Gasparovic H, Petricevic M, Biocina B. Letter by Gasparovic, et al. regarding article, ‘Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial’. Circulation 2011;124:e193–6 | A |
| Gasparovic H, Petricevic M, Biocina B. Reduction of thienopyridine-associated bleeding using multiple electrode whole-blood aggregometry. Ann Thorac Surg 2011;92:778–9 | A |
| Gavrilov AO, Shilov AM. [Characteristics of the thromboelastogram indices of the arterial and venous blood acute myocardial infarct.] Probl Gematol Pereliv Krovi 1979;24:27–9 | C, D |
| Gawaz M, Seyfarth M, Muller I, Rudiger S, Pogatsa-Murray G, Wolf B, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2009;87:332–6 | C, D |
| Geara AS, Azzi N, Bassil C, El-Sayegh S. Aspirin resistance in hemodialysis patients. Int Urol Nephrol 2012;44:323–5 | D |
| Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372–4 | C, D |
| Geisler T, Gawaz M, Steinhubl SR, Bhatt DL, Storey RF, Flather M. Current strategies in antiplatelet therapy – does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? Pharmacol Ther 2010;127:95–107. [Erratum published in Pharmacol Ther 2010;128:385] | A |
| Geisler T, Gawaz M. Editorial on ‘Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy’ by Marcucci, et al.
Thromb Haemost 2007;98:705–6 | A |
| Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54–61 | C |
| Geisler T, Htun P, Fateh-Moghadam S, Bischofs C, Mueller K, Bigalke B, et al. Responsiveness to clopidogrel adversely influences outcome in patients with chronic kidney disease undergoing coronary interventions. Eur Heart J 2010;31:341 | C |
| Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B, et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743–7 | D |
| Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420–5 | C |
| Geisler T, Zurn C, Paterok M, Gohring-Frischholz K, Bigalke B, Stellos K, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635–43 | C |
| Geisler T, Zurn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010;31:59–66 | C |
| Ghosh K, Shetty S, Mota L. Aspirin resistance in patients with coronary artery disease – which test to use in routine management? Blood Coagul Fibrinolysis 2008;19:324–6 | D |
| Gibbings G. No easy way to identify aspirin resistance. Practitioner 2008;252:6 | A |
| Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, et al. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol 2006;98:761–3 | A |
| Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J 2000;140:81–93 | C |
| Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806–11 | C |
| Giusti B, Saracini C, Vestrini A, Magi A, Marcucci R, Rossi L, et al. Genetic variants besides CYP2C19*2 polymorphism are associated with major adverse cardiovascular events in high risk vascular patients on dual antiplatelet therapy. Eur Heart J 2010;31:156 | C |
| Glauser J, Emerman CL, Bhatt DL, Peacock WF. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. Am J Emerg Med 2010;28:440–4 | B |
| Gluszek J, Posadzy-Malaczynska A, Tykarski A, Pupek-Musialik D, Gracz M, Kara-Perz H. Acetylsalicylic acid (aspirin) test for the diagnosis of renovascular hypertension. Clin Invest Med 1997;20:171–5 | D |
| Golanski J, Chizynski K, Golanski R, Watala C. [Application of platelet function analyzer (PFA-100TM) and whole blood aggregometry to monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it possible to reliably monitor antiplatelet treatment using routine laboratory diagnostic methods?] Pol Arch Med Wew 2000;104:355–61 | D |
| Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66:222–32 | D |
| Gordon B, Biss T, Butt T, McDiarmid A, Oezalp F, Pillay T, et al. Platelet mapping thromboelastography for individualized antiplatelet treatment after implantation of the HeartWare ventricular assist device. J Heart Lung Transplant 2011;30(Suppl. 1):S208–9 | D |
| Gorog DA, Douglas H, Ahmed N, Lefroy DC, Davies GJ. Coronary angioplasty enhances platelet reactivity through von Willebrand factor release. Heart 2003;89:329–30 | B, D |
| Gratsianskii NA. [Antiplatelet therapy in coronary heart disease. Some problems and achievements.] Kardiologiia 2010;50:4–21 | A |
| Gray EN, Cheema FH. Letter to the editor. ASAIO J 2008;54:138 | A |
| Green D. Prevention of thromboembolism after spinal cord injury. Sem Thromb Hemost 1991;17:347–50 | A |
| Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689 | C |
| Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs 2010;24:1027–40 | A |
| Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011;22:188–95 | D |
| Gritsiuk AI, Sopina NV. [Blood coagulation and fibrinolytic system in patients with marked coronary arteriosclerosis.] Kardiologiia 1970;10:9–16 | C, D |
| Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;63:587–93 | D |
| Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103:1245–53 | D |
| Grove EL, Hvas AM, Kristensen SD. Aspirin resistance: myth or major problem? Scand J Clin Lab Invest 2008;68:257–9 | A |
| Grove EL, Hvas AM, Kristensen SD. Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy. Kardiol Pol 2008;66:478–9 | A |
| Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63–6 | D |
| Guan SY, Han YL, Li Y, Guo L, Yang BS, Wang SL, et al. [Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2012;40:25–9 | C |
| Guha S, Mookerjee S, Guha P, Sardar P, Deb S, Roy PD, et al. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. Indian Heart J 2009;61:348–52 | D |
| Gupta MC, Dhamija JP, Mathur DS, Sharma BM. Role of propranolol and aspirin in decreasing platelet aggregation in occlusive cerebrovascular diseases. J Assoc Physicians India 1983;31:565–7 | D |
| Gupta S, Gupta MM. Aspirin and clopidogrel resistance – a myth or reality: an update. Indian Heart J 2008;60:245–53 | A |
| Gupta S, Gupta VK, Dhamija RK, Kela AK. Platelet aggregation patterns in normotensive and hypertensive subjects. Indian J Physiol Pharmacol 2002;46:379–82 | B |
| Gupta S. When aspirin doesn’t work. Time 2002;159:83 | A |
| Gurbel P, Bliden KP, Tantry U. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’: a rebuttal. J Thromb Haemost 2007;5:1087–8 | A |
| Gurbel P. Aspirin – Scope and limitations. Br J Cardiol 2010;17(Suppl. 1):S8–9 | A |
| Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event. J Thromb Haemost 2009;7:572 | C |
| Gurbel PA, Bilden KP, Tantry US. Diagnostics for aspirin resistance. Mol Diagn Ther 2008;12:55–6 | A |
| Gurbel PA, Bliden KP, Antonino MJ, Gesheff T, Cummings CC, Dubois BV, et al. Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. Thromb Res 2012;129:1–2 | C |
| Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820–6 | C |
| Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13 | C |
| Gurbel PA, Bliden KP, Kreutz RP, Dichiara J, Antonino MJ, Tantry US. The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. Platelets 2009;20:97–104 | C |
| Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827–32 | D |
| Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153–9 | C |
| Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123–5 | C |
| Gurbel PA, Jeong Y-H, Mahla E, Bliden K, Tantry U. The association of preoperative platelet function testing and bleeding in patients undergoing elective coronary artery bypass grafting. J Am Coll Cardiol 2012;59(Suppl. 1):E1455 | B, D |
| Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J Invasive Cardiol 2009;21:172–8 | A |
| Gurbel PA, Mahla E, Tantry US. Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. Thromb Haemost 2011;106:248–52 | A |
| Gurbel PA, Tantry US. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Circulation 2012;125:1276–87 | A |
| Gurbel PA, Tantry US, Shuldiner AR. The worry about clopidogrel ‘nonresponsiveness’: identification and treatment in the post-percutaneous coronary intervention patient. JACC Cardiovasc Interv 2009;2:1102–4 | A |
| Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv 2010;3:1008–10 | A |
| Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011;305:1136–7 | A |
| Gurbel PA, Tantry US. Antiplatelet resistance – fact or myth? Am Heart Hosp J 2009;7:50–7 | A |
| Guthikonda S, Kleiman NS. Is aspirin resistance valid? Future Cardiol 2006;2:1–4 | A |
| Ha SJ, Woo JS, Kim WS, Kim SJ, Kim W, Kim MK, et al. The effect of cilostazol adding or clopidogrel doubling on platelet function with diabetes mellitus and coronary artery disease on dual antiplatelet therapy. Eur Heart J 2010;31:975 | C, D |
| Hackeng CM, Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJT, et al. Prospective comparison of platelet function tests in predicting clinical outcome in 1069 patients undergoing coronary stent implantation: the popular study. Pathophysiol Haemost Thromb 2010;37:A129 | C |
| Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002;105:1620–2 | A |
| Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004;328:477–9 | A |
| Harding S, Johnston L, Michel J, Ramanathan A, La FA, Sasse A, et al. High on treatment platelet reactivity is common and differs among ethnic groups. Heart Lung Circul 2011;20:S34–5 | D |
| Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 2012;22:169–75 | C |
| Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011;9:1892–901 | C |
| Harmsze AM, van Werkum JW, ten Berg JM, Ruven HJT, Hackeng CM, Tjoeng MM, et al. Effect of genetic variants on the effectiveness of clopidogrel. Pharm Weekbl 2011;146:79–84 | B, C |
| Harrison P, Keeling D. Platelet hyperactivity and risk of recurrent thrombosis. J Thromb Haemost 2006;4:2544–6 | A |
| Harrison P, Mumford A. Screening Tests of Platelet Function: Update on their Appropriate Uses for Diagnostic Testing. New York, NY: Thieme; 2009 | A |
| Harrison P. The influence of citrate concentrations on PFA-100 closure times, platelet hyper-reactivity and aspirin monitoring. Thromb Res 2010;126:e137–8 | D |
| Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004;110:1706–8 | A |
| Henry P, Drouet L. Resistances to antiplatelet agents. Arch Mal Coeur Vaiss Prat 2010;16:14–21 | A |
| Hezard N, Tessier-Marteau A, Macchi L. New insight in antiplatelet therapy monitoring in cardiovascular patients: from aspirin to thienopyridine. Cardiovasc Hematol Disord Drug Targets 2010;10:224–33 | A |
| Hillarp A, Lethagen S, Mattiasson I. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity. J Thromb Haemost 2003;1:196–7 | A |
| Hillegass WB, Zoghbi G, Brott BC, Kilgore ML, Chapman GD, Misra VK. Cost-effectiveness of new oral antiplatelet agents and testing strategies during early invasive management of acute coronary syndrome patients. Circulation 2011;124(Suppl. 1):A18228 | B |
| Hillman RS. Platelet aspirin resistance detection and validation. J Am Coll Cardiol 2006;47:2565 | A |
| Hjemdahl P. Platelet reactivity, exercise, and stable coronary artery disease. Eur Heart J 1995;16:1017–19 | A |
| Hjemdahl P. Should we monitor platelet function during antiplatelet therapy? Heart 2008;94:685–7 | A |
| Ho WK, Hankey GJ, Eikelboom JW. Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure? Blood Coagul Fibrinolysis 2004;15:129–30 | A |
| Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59–64 | D |
| Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742–50 | C |
| Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600 mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560–4 | C |
| Hodges JS. Incorrect p value in: comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:1257 | A |
| Hoffmann S. Do platelet function assays predict clinical outcomes in clopidogrel pretreated patients undergoing elective PCI? Herz 2010;35:50 | A |
| Hokimoto S, Mizobe M, Chitose T, Kaikita K, Nakagawa K, Ogawa H. Impact of CYP2C19 polymorphism and diabetes mellitus on platelet reactivity and clinical outcomes in patients following coronary stent placement. Circulation 2011;124(Suppl. 1):A15054 | B, C |
| Hokimoto S, Ogawa H. Is it safe to use a proton pump inhibitor with clopidogrel? A comparison of clopidogrel with or without rabeprazole in Japan. Gastroenterology 2010;138(Suppl. 1):S498 | C |
| Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704–14 | B, C |
| Hong DM, Jeon YS, Kim JH, Lim TW, Lim YJ, Bahk JH, et al. Preoperative platelet response to collagen is associated with myocardial injury after off-pump coronary bypass graft in patients taking aspirin. Korean J Anesth 2010;58:129–35 | D |
| Hong JM, Shin DH, Lee JS. Comparison of platelet aggregation with thienopyridines in acute cerebral ischemia. Cerebrovasc Dis 2011;31:262–3 | B |
| Horiuchi H, Ikeda T, Taniguchi R, Kita T, Kimura T, Hisanori H. Characterization of the antiplatelet effect of aspirin at enrollment and after a 2-year follow-up in the real clinical setting in Japan. J Mol Cell Cardiol 2010;48(Suppl. 1):S115 | D |
| Houel R, Mazoyer E, Kirsch M, Boval B, Drouet L, Loisance DY. Resistance to aspirin after external ventricular assist device implantation. J Thorac Cardiovasc Surg 2003;126:1636–7 | D |
| Hovens MM, Snoep JD, Eikenboom JC, Van Der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175–81 | D |
| Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011;22:627–33 | C |
| Hu DY, Sun YH. [The current concept of aspirin resistance.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2006;34:1057–8 | A |
| Huang Y, Gueyffier F, Boissel JP, Nony P. Can poor-compliance be considered as an important cause for aspirin resistance? An ‘in-silico’ approach. Fundam Clin Pharmacol 2010;24:62 | A |
| Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Grabowski M, et al. Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. Platelets 2011;22:521–9 | C |
| Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Opolski G. Variable response in platelet reactivity to 600 mg clopidogrel-loading dose influences prognosis in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2009;53:A428 | B, C |
| Huczek Z, Filipiak KJ, Kochman J, Piatkowski R, Grabowski M, Roik M, et al. Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty – influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J 2007;154:62–70 | C |
| Huczek Z, Filipiak KJ, Kochman J, Piatkowski R, Grabowski M, Roik M, et al. Prognostic significance of platelet function in the early phase of ST-elevation myocardial infarction treated with primary angioplasty. Med Sci Monit 2008;14:CR144–51 | C |
| Hulot J-S, Collet J-P, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4:422–8 | C |
| Husstedt IW, Grotemeyer KH, Evers S, Staschewski F, Wertelewski R. Progression of distal symmetric polyneuropathy during diabetes mellitus: clinical, neurophysiological, haemorheological changes and self-rating scales of patients. Eur Neurol 1997;37:90–4 | D |
| Ibrahim K. Increased rate of stent thrombosis due to clopidogrel resistance in patients in therapeutic hypothermia after sudden cardiac death. Eur Heart J 2011;32:252 | C |
| Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schomig A, et al. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemost 2007;98:852–7 | C |
| Ikeda T, Taniguchi R, Watanabe S, Kawato M, Kondo H, Shirakawa R, et al. Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan. Circ J 2010;74:1227–35 | D |
| Inoue Y, Shimizu M, Hasuda T, Uehara Y, Nakae S, Kubota T, et al. Effect of platelet aggregation inhibition by aspirin and clopidogrel in post stenting patients. J Mol Cell Cardiol 2010;48(Suppl. 1):S173 | D |
| Isbir S, Ak K, Aksoy N. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005;28:514–15 | A |
| Israelian LA, Lubnin AI, Tseitlin AM. [Thromboelastography as a method for preoperative assessment of hemostasis state in neurosurgical patients on long term aspirin therapy.] Anesteziol Reanimatol 2011;4:27–32 | C |
| it-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ 2012;21:12–21 | A |
| Itoh T, Nakai K, Ono M, Hiramori K. Can the risk for acute cardiac events in acute coronary syndrome be indicated by platelet membrane activation marker P-selectin? Coron Artery Dis 1995;6:645–50 | B |
| Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, et al. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. Thromb Haemost 2008;100:648–54 | C |
| Ivanova NA. [Some indices of the blood coagulation system and thrombus-formation in patients with diabetes mellitus.] Kardiologiia 1971;11:121–5 | C, D |
| Izaguirre-Avila R, de la Pena-Diaz A, Barinagarrementeria-Aldatz F, Gonzalez-Pacheco H, Ramirez-Gutierrez AE, Ruiz-Sandoval JL, et al. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002;8:169–77 | B, C |
| Jackson AN, Hume AL. Aspirin for CV prevention – for which patients? J Fam Pract 2011;60:518–23 | A |
| Jafri SM, Riddle JM, Raman SB, Goldstein S. Altered platelet function in patients with severe congestive heart failure. Henry Ford Hosp Med J 1986;34:156–9 | D |
| Jaremo P, Milovanovic M, Lindahl TL, Richter A. Elevated platelet density and enhanced platelet reactivity in stable angina pectoris complicated by diabetes mellitus type II. Thromb Res 2009;124:373–4 | D |
| Jeon HW, Cha JK. Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonography. J Thromb Thrombolysis 2008;25:265–9 | D |
| Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol 2010;64:51–7 | D |
| Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010;3:17–26 | C, D |
| Jeong Y-H, Hwang S-J, Park Y, Kim I-S, Kwak CH, Hwang J-Y. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2010;55(Suppl. 1):A130 | C, D |
| Jeong Y-H, Kim I-S, Choi B-R, Kwak CH, Hwang J-Y. The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay. Eur Heart J 2008;29:2186–7 | C |
| Jeong Y-H, Kim I-S, Park Y, Yun S-E. Platelet inhibition by adjunctive cilostazol vs. high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. J Thromb Haemost 2011;9:48–9 | D |
| Jeong Y-H, Koh J-S, Kwon TJ, Park Y, Kim I-S. Impact of the cytochrome P450 2C19*3 polymorphism on platelet reactivity and adverse clinical events in patients with acute myocardial infarction. J Thromb Haemost 2011;9:793 | B, C |
| Jeong Y-H, Kwon TJ, Tantry US, Park Y, Hwang S-J, Bliden KP, et al. Correlation between platelet reactivity and type of post-discharge bleeding events in PCI-treated patients: results of the ACCEL-BLEED study. J Am Coll Cardiol 2011;58(Suppl. 1):B221 | B, C |
| Jeong Y-H, Lee K, Yoo S-Y, Park J-H, Suh J, Park K-H. Accelerated inhibition of platelet aggregation, inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome: the results of the ACCEL-LOADING-ACS multicenter randomized trial. J Am Coll Cardiol 2012;59(Suppl. 1):E455 | C |
| Jeong Y-H, Lee K, Yoo S-Y, Park J-H, Suh J, Park KH. Multicenter randomized trial evaluating the efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in ACS patients undergoing PCI: the results of accel-loading-ACS (accelerated inhibition of platelet aggregation, inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome) trial. Am J Cardiol 2012;109(Suppl. 1):1S–2S | C |
| Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. Heart 2012;98:343–4 | D |
| Jeong YH, Tantry US, Bliden KP, Gurbel PA. Cilostazol to overcome high on-treatment platelet reactivity in Korean patients treated with clopidogrel and calcium-channel blocker. Circ J 2011;75:2534–6 | A |
| Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4:585–94 | C |
| Jeong YH, Tantry UT, Jung TJ, Park YH, Kim IS, Bliden KA, et al. Impact of the cytochrome P450 2C19*3 polymorphism on platelet reactivity and adverse clinical events in patients with acute myocardial infarction. Eur Heart J 2011;32:508 | C |
| Jeong Y-H, Yongwhi P, In-Suk K, Tae JK, Jin-Yong H. The influence of genetic polymorphism and drug–drug interaction on antiplatelet effect in patients treated with long-term dual antiplatelet therapy. J Thromb Haemost 2011;9:75–6 | D |
| Jha AK. Using aspirin resistance to predict long-term cardiovascular outcomes. J Clin Outcomes Manage 2007;14:491 | A |
| Jian C, Lin L, Li F. Prevalence and risk factors for aspirin resistance in older patients with cardiovascular disease. Heart 2011;97(Suppl. 3):A101 | D |
| Jilma B, Fuchs I. Aspirin. Methods to assess aspirin resistance. J Thromb Haemost 2004;2:337–8 | A |
| Jilma B, Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 2001;88:1348–9 | A |
| Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003;34:849–54 | A |
| Jilma B. Therapeutic failure or resistance to aspirin. J Am Coll Cardiol 2004;43:1332–3 | A |
| Johns A, Fisher M, Knappertz V. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:1754–5 | A |
| Johnson GJ, Sharda AV, Rao GH, Ereth MH, Laxson DD, Owen WG. Measurement of shear-activated platelet aggregate formation in non-anticoagulated blood: utility in detection of clopidogrel-aspirin-induced platelet dysfunction. Clin Appl Thromb Hemost 2012;18:140–9 | D |
| Jukema JW, Collet J-P, De Luca L. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Curr Med Res Opin 2012;28:203–11 | C |
| Jungmayr P. Cardiovascular morbidity: clinical relevance of aspirin resistance. Dtsch Apoth Ztg 2008;148:43–4 | A |
| Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104:181–6 | C |
| Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider DJ. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 2003;91:876–8 | C |
| Kakouros N, Kickler TS, Laws K, Rade JJ. Hematocrit significantly affects the results of the verifynow assay in patients receiving dual antiplatelet therapy. Circulation 2011;124(Suppl. 1):A17082 | D |
| Kakuliia MS, Panchenko VM. [Functional status of thrombocytes in patients with acute forms of ischemic heart disease.] Klin Med (Mosk) 1987;65:88–92 | B, C, D |
| Kalyanasundaram A, Berger PB. Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:284–7 | A |
| Kang HS, Kwon BJ, Kim JE, Han MH. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. Am J Neuroradiol 2010;31:1206–10 | C |
| Kapoor JR. Enteric coating is a possible cause of aspirin resistance. J Am Coll Cardiol 2008;52:1276–7 | A |
| Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004;25:419–23 | C |
| Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg 2009;50:1500–10 | A |
| Kaymaz C, Tanboga IH, Tokgoz HC, Poci N, Can MM, Kirca N, et al. Clinical, procedural, cardiometabolic and laboratory correlates of platelet reactivity to clopidogrel and aspirin on multiplate analyser in patients with coronary stenting. Eur Heart J 2011;32:752–3 | D |
| Kerenyi A, Soltesz P, Veres K, Szegedi G, Muszbek L. Monitoring platelet function by PFA-100 closure time measurements during thrombolytic therapy of patients with myocardial infarction. Thromb Res 2005;116:139–44 | D |
| Kim C-H, Park K-W, Jeon K, Kang S-H, Kim K-H, Lee H-Y, et al. Decreased response to clopidogrel is a risk factor for cardiovascular events after stent implantation: Cross verify study. J Am Coll Cardiol 2010;55(Suppl. 1):A51 | C |
| Kim H-L, Suh J-W, Lee S-P, Oh I-Y, Kang H-J, Koo B-K, et al. No legacy effect of six months’ treatment of cilostazol on the long-term prognosis of patients who underwent drug-eluting stent implantation: 2-year follow-up of the cilon-t trial. J Am Coll Cardiol 2012;59(Suppl. 1):E1404 | C |
| Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S. The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7:897–9 | B, C, D |
| Kim IS, Jeong YH, Kang MK, Koh JS, Park Y, Hwang SJ, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis 2010;30:486–95 | C |
| Kim J-Y, Yoon J. Aspirin and clopidogrel resistance in drug eluting stent era. Korean Circ J 2007;37:135–47 | A |
| Kim KE, Woo KS, Goh RY, Quan ML, Cha KS, Kim MH, et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. Int J Lab Hematol 2010;32:50–5 | D |
| Kim MH, Yu LH, Kim JH, Park SY, Park TH, Cha KS, et al. Initial loading therapy of cilostazol improved antiplatelet responsiveness in patient with percutaneous coronary intervention. J Am Coll Cardiol 2010;55(Suppl. 1):A208 | D |
| King A, Bath PM, Markus HS. Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 2011;42:650–5 | C |
| King A, Bath PMW, Markus H. What is the best antiplatelet regimen in acute carotid stenosis? A randomised trial comparing clopidogrel versus dipyridamole in addition to aspirin on asymptomatic embolisation. Cerebrovasc Dis 2010;29:160–1 | C |
| Kirtane AJ, Parise H, Witzenbichler B, Weisz G, Rinaldi M, Neumann F-J, et al. Does platelet function testing add significant incremental risk stratification to unselected patients undergoing des implantation? The adapt-des study. J Am Coll Cardiol 2012;59(Suppl. 1):E292 | C |
| Kirtane AJ, Rinaldi M, Parise H, Witzenbichler B, Weisz G, Neumann F-J, et al. Impact of point-of-care platelet function testing among patients with and without acute coronary syndromes undergoing PCI with drug-eluting stents: An ADAPT-des substudy. J Am Coll Cardiol 2012;59(Suppl. 1):E291 | C |
| Kirtane AJ, Stuckey T, Parise H, Witzenbichler B, Weisz G, Rinaldi M, et al. Impact of point-of-care platelet function testing among diabetic and non-diabetic patients undergoing PCI with drug-eluting stents: an adapt-des substudy. J Am Coll Cardiol 2012;59(Suppl. 1):E268 | B |
| Kleiman NS. Could clopidogrel’s platelet inhibition be enhanced by an increased loading dose and eptifibatide? Nat Clin Pract Cardiovasc Med 2005;2:344–5 | A |
| Kliger C, Babaev A, Shah B, Feit F, Slater J, Attubato M. Dual antiplatelet therapy responsiveness in patients undergoing percutaneous revascularization for peripheral arterial occlusive disease. J Am Coll Cardiol 2012;59(Suppl. 1):E2049 | D |
| Kobune K, Inoue M, Morikawa M, Tsuboi M, Takanami Y, Iwane Y, et al. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement. Res Comm Chem Pathol Pharmacol 1991;74:153–65 | D |
| Koerner H, Derveaux C, Alexandrou M, Graeber S, Roth C, Papanagiotou P, et al. Do clopidogrel nonresponders have an increased risk of adverse events during supra-aortal angioplasty and stenting? Stroke Res Treat 2012;2012:904534 | C |
| Konorza TFM. TAILORED: tailored clopidogrel loading doses according to platelet reactivity monitoring decrease early stent thrombosis. Herz 2009;34:74 | C |
| Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1994;9:1115–20 | A |
| Koscielny J, Aslan T, Meyer O, Kiesewetter H, Jung F, Mrowietz C, et al. Use of the platelet reactivity index by Grotemeyer, platelet function analyzer, and retention test Homburg to monitor therapy with antiplatelet drugs. Semin Thromb Hemost 2005;31:464–9 | B, D |
| Koscielny J, Meyer O, Kiesewetter H, Jung F, Latza R. [Platelet reactivity index by Grotemeyer.] Hamostaseologie 2004;24:207–10 | A |
| Kottke BA. The ultimate solution to the problem of aspirin resistance. J Am Coll Cardiol 2008;52:1276 | A |
| Koul S, Andell P, Martinsson A, Smith JG, Schersten F, Harnek J, et al. Upstream clopidogrel followed by pre-PCI prasugrel gives rapid platelet inhibition and represents a feasible option in STEMI patients undergoing primary PCI. J Am Coll Cardiol 2012;59(Suppl. 1):E526 | C |
| Kour D, Tandon VR, Kapoor B, Mahajan A, Parihar A, Smotra S. Aspirin resistance. JK Science 2006;8:116–17 | A |
| Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bachorzewska H, Gugala K, et al. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction. Kardiol Pol 2004;60:459–67 | C |
| Kramer MC, Nieuwland R, Sturk A, de Winter RJ. [Routine platelet aggregation inhibition not useful when using acetylsalicylic acid or clopidogrel.] Ned Tijdschr Geneeskd 2009;153:190–5 | A |
| Kratzer MA. Platelet function analyzer (PFA)–100 closure time in the evaluation of platelet disorders and platelet function: a rebuttal. J Thromb Haemost 2006;4:1845–6 | A |
| Kremneva LV, Shalaev SV. [Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction.] Ter Arkh 2008;80:89–95 | A |
| Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? The role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 2012;125:1288–303 | A |
| Kronish IM, Rieckmann N, Shimbo D, Davidson KW. Letter by Kronish, et al. regarding article, ‘Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance’. Circulation 2007;115:e45 | A |
| Kubik MM, Richardson SG. A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone. Postgrad Med J 1987;63:351–6 | B |
| Kudaravalli J, Deshpande N, Avanapu SR, Vijaya LG, Nagaveni. Evaluation of aspirin resistance in elderly people in rural population in India. Der Pharm Lett 2011;3:5–9 | D |
| Kuliczkowski W, Halawa B, Korolko B, Mazurek W. Aspirin resistance in ischaemic heart disease. Kardiol Pol 2005;62:14–25 | D |
| Kusunoki M, Kimura K, Nagatsuka K, Isaka Y, Uyama O, Yoneda S, et al. Platelet hyperaggregability in ischemic cerebrovascular disease and effects of aspirin. Thromb Haemost 1982;48:117–19 | D |
| Kuzniatsova N, Shantsila E, Blann AD, Tse HF, Lip GYH. Is increased arterial stiffness related to aspirin responsiveness in patients with coronary artery disease: a possible mechanism for increased cardiovascular events in aspirin non-responders? Eur Heart J 2011;32:253 | D |
| Kwok CS, Loke YK. Critical overview on the benefits and harms of aspirin. Pharmaceuticals 2010;3:1491–506 | C |
| Kwon SU, Lee J-H, Cha J-K, Lee SJ, Ha S-W. Addition of cilostazol reduce biochemical aspirin resistance in aspirin users with ischemic stroke. Stroke 2009;40:e270 | D |
| Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon AP, et al. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004;44:2091–3 | A, C, D |
| Lam H, Chan CK, Yip SF, Yam PW, Chui KL, Chan YH, et al. Monocyte platelet aggregate act as platelet function assay and prognostic marker for acute myocardial infarction. J Am Coll Cardiol 2011;58(Suppl. 1):B95 | C |
| Lam W, Gill JB, Trask RV, Mallavarapu CT, Rocha-Singh KJ, Mikell FL, et al. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J 2001;141:402–9 | C |
| Lancaster G. Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease. Clin Cardiol 2006;29:334 | A |
| Lanza GA, Scalone G, Battipaglia I, Barone L, Coviello I, Milo M, et al. Evidence of increased platelet reactivity in the first six months after acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2011;57(Suppl. 1):E1093 | C |
| Lassar TA, Simon DI, Croce K. Optimizing antiplatelet therapy following percutaneous coronary intervention: clinical pathways for platelet function testing. Rev Cardiovasc Med 2011;12(Suppl. 1):S23–33 | A |
| Latour JG, Theroux P, Bourassa MG. Sulfinpyrazone decreases epinephrine-induced platelet aggregation after myocardial infarction. Am J Cardiol 1982;50:938–44 | B |
| Lee K, Lee S-W, Lee J-W, Kim S-Y, Youn Y-J, Ahn M-S, et al. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the VerifyNow P2Y12 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009;39:512–18 | C |
| Lee KH, Lee SH, Lee JW, Sung JK, Wang HS, Youn YJ, et al. The significance of clopidogrel low-responsiveness assessed by a point-of-care assay in acute coronary syndrome patients undergoing coronary stenting. Eur Heart J 2009;30:328 | C |
| Lee SJ, Kim JG, Ko Y, Lee BH. Clopidogrel-induced platelet inhibition may predict early ischemic complications following stent-assisted angioplasty for symptomatic cerebral atherosclerotic disease. Stroke 2011;42:e96 | C |
| Lee SP, Bae JW, Park KW, Rha SW, Bae JH, Suh JW, et al. Inhibitory interaction between calcium channel blocker and clopidogrel. Efficacy of cilostazol to overcome it. Circ J 2011;75:2581–9 | C |
| Lee S-P, Suh J-W, Park KW, Lee H-Y, Kang H-J, Koo B-K, et al. Study design and rationale of ‘Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)’ study: a multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials 2010;11:87 | A |
| Legrand V, Barbato E, Chenu P, Wijns W. Platelet reactivity after ASA and clopidogrel treatment assessed with VerifyNow point-of-care analysis in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Eurointervention 2010;6(Suppl. H):12 | D |
| Lemesle G, Mokhtar OA, Armero S, Mancini J, Bonello C, Tahirou I, et al. Relationship between platelet reactivity inhibition and major bleeding in patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med 2010;11:207 | C |
| Leone G, Valori VM, Sandric S, Cudillo L, Bizzi B. Platelet activation and thromboembolism in patients with mitral valve prolapse. Thromb Res 1982;28:831–5 | D |
| Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27–33 | D |
| Lev EI. Aspirin resistance transient laboratory finding or important clinical entity? J Am Coll Cardiol 2009;53:678–80 | A |
| Levine PL. Editorial. Platelet-function tests: predictive value. New Engl J Med 1975;292:1346–7 | A |
| Li JS, Eric Y, Berezny KY, Bokesch PM, Takahashi M, Graham J, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial. Circulation 2008;117:553–9 | B, C |
| Li Y, Han Y, Wang S, Li C, Mai X, Jing Q, et al. Effects of laboratory test guided, individually tailored antiplatelet therapy after percutaneous coronary artery intervention. Circulation 2010;122:e67 | C |
| Lian J, Azmi S, Navaratnam P. Gaps and unmet needs in antiplatelet therapies for acute coronary syndrome (ACS) and chronic coronary heart disease (CHD). Value Health 2011;14:A47 | C |
| Lievykh AE, Mamchur VI, Rodionova VV, Bespala DV. Thiotriazolin enhances antiaggregatory activity of acetylsalicilic acid and reduces its gastrotoxicity in patients with coronary heart disease. Basic Clin Pharmacol Toxicol 2011;109:100 | D |
| Lim E, Carballo S, Cornelissen J, Ali ZA, Grignani R, Bellm S, et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl(A2) polymorphism (NCT00262275). Ann Thorac Surg 2007;83:134–8 | D |
| Liu L, Lin Z, Shen Z, Zhang G, Li S, Cao P. Platelet hyperfunction exists in both acute non-haemorrhagic and haemorrhagic stroke. Thromb Res 1994;75:485–90 | B, D |
| Liu P-Y, Hsu L-J, Lee P-T, Lee C-H, Chen J-Y, Li Y-H, et al. Clopidogrel hyporesponsiveness, interacting with diabetes mellitus, predicts 2-year cardiovascular outcome among Taiwanese population underging percutaneous coronary intervention. J Am Coll Cardiol 2011;58(Suppl. 1):B114 | C |
| Liusov VA. [State of the blood coagulation system in patients with myocardial infarct and chest pain and the changes in it during the use of anticoagulants and fibrinolysin.] Kardiologiia 1967;7:29–35 | D |
| Lo PR, D’Amico T, Montana M, Canino B, Romano A, Caimi G. Platelet activation markers in long-term follow-up of young subjects with acute myocardial infarction. Clin Hemorheol Microcirc 2006;35:527–8 | C |
| Loew D, Vinazzer H. Influence of simultaneous administration of low-dose heparin and acetylsalicylic acid on blood coagulation and platelet functions. Haemostasis 1974;3:319–28 | B, D |
| Lordkipanidze M, Pharand C, Diodati JG. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic (reply). Eur Heart J 2008;29:138–9 | A |
| Lotrionte M, Biondi-Zoccai GG, Agostoni P, Sheiban I. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic. Eur Heart J 2008;29:138–9 | A |
| Lu YL, Chen YD, Lu SZ. [Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2007;35:793–6 | C |
| Lutsep H. Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Exp Rev Cardiovasc Ther 2011;9:1295–303 | A |
| Luxembourg B, Mani H, Toennes SW, Strubel G, Klaeffling C, Daemgen-von Brevern G, et al. Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions. Thromb Haemost 2007;97:1046–8 | A |
| Luzak B, Boncler M, Rywaniak J, Wilk R, Stanczyk L, Czyz M, et al. The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. Eur J Pharmacol 2011;658:91–7 | D |
| Luzak B, Boncler M, Rywaniak J, Wilk R, Stanczyk L, Rysz J, et al. The effect of platelet and plasma oxLDL and platelet cholesterol on the ASA-mediated blood platelet inhibition and platelet protein acetylation in atorvastatin-treated hypercholesterolemic patients. J Thromb Haemost 2009;7:349 | D |
| Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006;98:1–5 | A |
| Lynch DR, Jr, Khan FH, Vaidya D, Williams MS. Persistent high on-treatment platelet reactivity in acute coronary syndrome. J Thromb Thrombolysis 2012;33:267–73 | D |
| Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost 2004;2:2051–3 | D |
| Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002;144:151–8 | B |
| Madsen EH, Gehr NR, Johannesen NL, Schmidt EB, Kristensen SR. Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets 2011;22:537–46 | D |
| Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010;56:839–47 | D |
| Madsen EH, Schmidt EB, Gehr N, Johannesen NL, Kristensen SR. Testing aspirin resistance using the Platelet Function Analyzer-100: some methodological caveats and considerations. J Thromb Haemost 2008;6:386–8 | D |
| Magd AKA, Elsawy E, Ramzy A, Ragy H, Okasha N. Is there a platelet rebound effect to stopping clopidogrel? Am J Cardiol 2009;104(Suppl. 1):173D | C |
| Maiorov I. [The status of the blood anticoagulation system in angina pectoris and myocardial infarct.] Kardiologiia 1968;8:24–30 | B |
| Malanowicz W. [A preliminary evaluation of thromboelastography in coronary heart diseases.] Pol Arch Med Wewn 1966;36:351–6 | B, D |
| Malek LA, Bilinska ZT, Sitkiewicz D, Klopotowski M, Witkowski A, Ruzyllo W. Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate. Thromb Res 2010;125:67–71 | D |
| Malek LA, Ruzyllo W. Bleeding and drug resistance – pitfalls of contemporary antiplatelet and antithrombotic treatment in cardiology. Postepy Kardiol Interwencyjnej 2008;4:74–9 | A |
| Malek LA, Spiewak M, Filipiak KJ, Grabowski M, Szpotanska M, Rosiak M, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007;65:40–5 | D |
| Malmstrom RE, Ostergren J, Jorgensen L, Hjemdahl P, CASTOR investigators. Poor performance with a platelet counting technique to monitor clopidogrel inhibitory effects in the point-of-care setting. Thromb Res 2010;125:473–4 | C, D |
| Mamelov I. [Thrombelastographic data in diseases of the peripheral vessels.] Vestn Khir Im I I Grek 1966;97:76–7 | B, C |
| Mandava P, Anderson J, Dalmeida W, Kent TA. Platelet inhibition may explain results with abciximab In the treatment of acute ischemic stroke. Cerebrovasc Dis 2009;27:16 | B, C, D |
| Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, et al. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010;3:318–23 | C |
| Mangiacapra F, Barbato E. Individual variability of response to antiplatelet therapy is an important determinant of adverse clinical outcome. High Blood Press Cardiovasc Prev 2010;17:121–30 | A |
| Mangiacapra F, Barbato E. Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers Med 2010;4:421–34 | A |
| Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, et al. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2010;3:35–40 | C |
| Mangiacapra F, Muller O, Trana C, Ntalianis A, Wijns W, De Bruyne B, et al. High platelet reactivity after clopidogrel correlates with the extent of coronary atherosclerosis and predicts peri-procedural outcome in patients with stable angina undergoing PCI. Eur Heart J 2009;30:199 | C |
| Mangiacapra F, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012;5:281–9 | C |
| Mangiacapra F, Patti G, Gatto L, Nusca A, Vizzi V, Ricottini E, et al. Inadequate platelet inhibition with clopidogrel measured by a point-of-care assay and poorer peri-procedural outcome in diabetic patients undergoing percutaneous coronary intervention. Eur Heart J 2009;30:784 | C |
| Mangiacapra F, Patti G, Peace A, Gatto L, Ricottini E, Vizzi V, et al. Validating ARMYDA-PRO/bleeds: A therapeutic window in platelet reactivity for patients undergoing elective percutaneous coronary intervention. G Ital Cardiol 2011;12(Suppl. 3):e8 | C |
| Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010;106:619–23 | C |
| Mani H, Lindhoff-Last E. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel.] Pharm Unserer Zeit 2009;38:342–50 | A |
| Mani H, Lindhoff-Last E. Response to Mortensen, et al. ‘Do the Behring Coagulation Timer (BCT) and the Platelet Function Analyzer PFA-100 identify the same patients as being aspirin non-responder?’ Platelets 2007;18:391–2 | A |
| Marcucci R, Gensini GF. High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. Intervent Cardiol 2010;2:619–21 | A |
| Marcucci R, Giusti B, Gori AM, Paniccia R, Saracini C, Vestri A, et al. Cardiovascular death and nonfatal MI in ACS patients are predicted by residual platelet reactivity to ADP in the absence of CYP2C19*2 allele: beyond genetic screening. Eur Heart J 2009;30:197 | C |
| Marcucci R, Gori AM, Giusti B, Paniccia R, Fabbri A, Cordisco A, et al. High on treatment platelet reactivity in acute coronary syndrome patients: an acute-phase reaction? Pathophysiol Haemost Thromb 2010;37:A132 | D |
| Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Response to letter regarding article, ‘cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up’. Circulation 2009;120:e99 | A |
| Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237–42 | C |
| Marcucci R, Paniccia R, Gori AM, Fabbri A, Antonucci E, Casola G, et al. Natural history of high on treatment platelet reactivity by ADP in patients with ACS undergoing PCI. J Thromb Haemost 2011;9:546 | C, D |
| Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196–207 | A |
| Maree AO, Jneid H, Fitzgerald DJ. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2006;48:846–7 | A |
| Martin JF, Bath PM, Burr ML. Mean platelet volume and myocardial infarction. Lancet 1992;339:1000–1 | A |
| Masik MG, Potapov BA, Kropel’nitskaia MV. [The status of the blood coagulation system during treatment of patients with diabetes mellitus.] Vrach Delo 1969;10:21–4 | C, D |
| Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171–5. [Erratum published in Circulation 2011;124:e459. Note: Bienart, Roy (corrected to Beinart, Roy)] | C |
| McCabe DJ, Harrison P, Machin SJ, Watt H, Brown MM. Measurement of the antiplatelet effects of aspirin in cerebrovascular disease. Stroke 2004;35:e146–7 | A |
| McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269–80 | D |
| McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004;126:861–9 | C |
| McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999;99:2892–900 | C |
| McGill D, McGuiness J, Lloyd J, Ardlie N. Platelet function and exercise-induced myocardial ischaemia in coronary heart disease patients. Thromb Res 1989;56:147–58 | B, D |
| McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711–15 | A |
| Meade TW, Cooper JA, Miller GJ. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 1997;78:926–9 | B |
| Medeiros FB, de Andrade AC, Angelis GA, Conrado VC, Timerman L, Farsky P, et al. Bleeding evaluation during single tooth extraction in patients with coronary artery disease and acetylsalicylic acid therapy suspension: a prospective, double-blinded, and randomized study. J Oral Maxillofac Surg 2011;69:2949–55 | D |
| Mehta AB, Mardikar HM, Shah S. Clopidogrel resistance: chemical curiosity or clinical enigma? Indian Heart J 2007;59:116–17 | A |
| Mehta H, Price MJ. Time to surgery and adverse events for patients receiving clopidogrel therapy. J Am Coll Cardiol 2011;57(Suppl. 1):E1939 | C |
| Mendez A, Huber AR. Aspirin resistance – a complex but serious phenomenon. J Kardiol 2010;17:68–9 | B, D |
| Mendolicchio GL, Zavalloni D, Corrada E, Rossi M, Marconi M, Bacci M, et al. Resistance to clopidogrel detected by real time evaluation of platelet thrombus formation. J Thromb Haemost 2009;7:896–7 | C |
| Mendolicchio GL. Efficacy assessment of antiplatelet therapy in acute coronary syndrome by time-volume analysis of platelet thrombus formation. Arterioscler Thromb Vasc Biol 2010;30:e223 | C |
| Mengistu AM, Mayer J, Boldt J, Rhm KD, Suttner SW. Usefulness of monitoring platelet function by multiple electrode aggregometry in primary coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2011;25:42–7 | C, D |
| Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203–6 | C |
| Mezzano D, Quiroga T, Pereira J. The Level of Laboratory Testing Required for Diagnosis or Exclusion of a Platelet Function Disorder Using Platelet Aggregation and Secretion Assays. New York, NY: Thieme; 2009 | A |
| Michelson AD. Aspirin resistance. Pathophysiol Haemost Thromb 2006;35:5–9 | A |
| Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006;35:67–82 | A |
| Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489–93 | A |
| Michelson AD. Platelet function testing in cardiovascular diseases. Hematology 2005;10(Suppl. 1):132–7 | A |
| Migliorini A, Valenti R, Giuliani G, Buonamici P, Cerisano G, Carrabba N, et al. Prognostic impact of nonresponsivness platelet residual reactivity to clopidogrel therapy in patients with left main disease treated with coronary drug-eluting stent implantation. Eur Heart J 2009;30:847–8 | B, C |
| Milovanovic M, Fransson E, Hallert C, Jaremo P. Atrial fibrillation and platelet reactivity. Int J Cardiol 2010;145:357–8 | D |
| Mishra P, Kotwal J, Dutta V, Singh N, Kotwal A. Prevalence of aspirin and clopidogrel resistance in cardiac patients. Indian J Hematol Blood Transfus 2011;27:236 | D |
| Moerenhout CM, Claeys MJ, Haine S, Miljoen H, Bosmans JM, Vertessen F, et al. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP. Am Heart J 2010;159:434–8 | C |
| Mokhtar OA, Lemesle G, Armero S, Mancini J, Bonello C, Tahirou I, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res 2010;126:e147–9 | C |
| Montalescot G, Sideris G, Meuleman C, Bal-Dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931–8 | C |
| Morel O, Bernhard N, Desprez D, Grunebaum L, Freyssinet JM, Toti F, et al. Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis? Thromb Haemost 2008;99:448–51 | C, D |
| Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011;57:399–408 | C |
| Morel O, Faure A, Ohlmann P, Jesel L, Desprez D, Grunebaum L, et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb Haemost 2007;98:896–9 | C |
| Moriyama Y, Toyohira H, Saigenji H, Shimokawa S, Taira A, Nakamura K. [Influence of acute aortic dissection, on platelet function second department of surgery, department of pharmacy: preliminary report.] Nippon Geka Gakkai Zasshi 1995;96:725 | D |
| Morris A, Aliprandi-Costa B, Brieger D. Platelet function analysis: a comparison of methods. Int J Cardiol 2010;145:167–8 | C |
| Mortensen J, Poulsen TS, Refsgaard J, Kristensen SD. Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders? Platelets 2007;18:389–90 | A |
| Motoda C, Ueda H, Hayashi Y, Toyofuku M, Okimoto T, Otsuka M, et al. Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina. Circ J 2012;76:641–9 | C |
| Motoyoshi K. Platelet function 2 weeks following stent implantation and its relation with factors for stent thrombosis. With special reference to the difference between silorimus-eluting and bare metal stents. Teikyo Med J 2007;30:111–20 | D |
| Mueller C, Neumann FJ, Hochholzer W, Trenk D, Zeller T, Perruchoud AP, et al. The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction. Am Heart J 2006;151:1214–17 | C |
| Muir AR, McMullin MF, Patterson C, McKeown PP. Associations between methods of measurement of aspirin resistance and their temporal variations in patients with ischaemic heart disease. Heart 2008;94:A137 | D |
| Muller-Schunk S, Linn J, Peters N, Spannagl M, Deisenberg M, Bruckmann H, et al. Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. Am J Neuroradiol 2008;29:786–91 | C |
| Murray S. Does sex affect how patients respond to ASA? CMAJ 2006;174:773 | A |
| Musumeci G, Valgimigli M, Sirbu V, Aprile A, Matiashvili A, Trivisonno A, et al. Correlation between stent strut coverage and platelet reactivity to predict outcome after coronary stenting. Eur Heart J 2009;30:674 | D |
| Myers RI. The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent) 2005;18:331–6 | A |
| Mylotte D, Foley D, Kenny D. Platelet function testing: methods of assessment and clinical utility. Cardiovasc Hematol Agents Med Chem 2011;9:14–24 | A |
| Nagata Y, Kurokawa K, Inomata J, Aburatani I, Maruyama M, Usuda K. Usefulness of the platelet aggregately index in predicting atherothrombotic event in patient undergoing coronary intervention. Am J Cardiol 2011;107(Suppl. 1):29A | C |
| Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al. Platelet dysfunction is associated with worse outcome after intracerebral hemorrhage. Stroke 2009;40:e234 | B |
| Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 2009;65:352–6 | D |
| Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 2009;40:2398–401 | B |
| Nava C, Recaldin E, Franchi F. [Hemocoagulation in myocardial infarct (thromboelastographic findings).] Acta Gerontol (Milano) 1967;17:146–68 | B |
| Navarro-Nunez L, Pastor F, Lozano M, Marin F, Hurtado J, Roldan V, et al. Comparison of four tests to assess platelet reactivity in patients under dual antiplatelet therapy. J Thromb Haemost 2009;7:570 | D |
| Nazarian SM, Thompson JB, Gluckman TJ, Laws K, Jani JT, Kickler TS, et al. Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy. Thromb Res 2010;126:379–83 | D |
| Neubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, Lask S, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance – the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3 | D |
| Nezami N, Nargabad ON, Ghorashi S. Letter by Nezami, et al. regarding article, ‘Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial’. Circulation 2012;125:e569 | A |
| Nishikawa M, Isshiki T, Ogawa H, Kimura T, Yokoi H, Nanto S, et al. Consistent and potent platelet inhibition of prasugrel irrespective of CYP2C19 polymorphism in Japanese patients with coronary artery disease. J Thromb Haemost 2011;9:336 | C, D |
| Nitta M, Yano H, Endo T, Tsukahara K, Hibi K, Kimura K, et al. Contributing factors to high on-treatment residual platelet reactivity in patients with acute coronary syndromes. J Am Coll Cardiol 2012;59(Suppl. 1):E520 | C |
| Noren I, Garde A. Value of blood coagulation tests in ischemic cerebral disease. Eur Neurol 1986;25:330–8 | D |
| Nowakowski P. In reply to the comment on antiplatelet treatment monitoring. Anest Intens Ter 2007;39:164–5 | A |
| Ntalianis A, Cuisset T, Hamilos M, Muller O, Mangiacapra F, Trana C, et al. PCI-related myocardial infarction in patients with renal insufficiency reloaded with clopidogrel: an open-label multicenter registry. Eur Heart J 2011;32:1039 | C |
| Ntalianis A, Trana C, Muller O, Mangiacapra F, Peace A, Hamilos M, et al. Safety and efficacy of reloading doses of clopidogrel and aspirin before elective PCI to optimize periprocedural outcome in elderly. Eur Heart J 2010;31:221 | D |
| Obergfell A, Strotmann J, Bonz A, Bauersachs J, Ertl G, Walter U, et al. Impaired platelet responses to clopidogrel and ticlopidine in a patient with recurrent coronary stent stenosis. Thromb Haemost 2004;92:1446–7 | A |
| O’Brien JR. Platelet function tests and thrombosis. Adv Exp Med Biol 1972;34:43–54 | A |
| O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989–97 | C |
| Oestreich JH, Steinhubl SR, Ferraris SP, Akers WS. High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. Thromb Haemost 2011;105:927–30 | C, D |
| Oh I-Y, Park KW, Kang S-H, Park JJ, Na S-H, Kang H-J, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98:139–44 | C |
| Oh I-Y, Yoon C-H, Park S-J, Park K-W, Lee H-Y, Cho H-J, et al. Cytochrome P450 2C19 loss-of-function polymorphism and cardiovascular events in patients treated with drug-eluting stent. J Am Coll Cardiol 2010;55(Suppl. 1):A113 | C |
| Ohlmann P, El Ghannudi S, Wiesel M-L, Radulescu B, Bareiss P, Chauvin M, et al. Platelet reactivity assessed by flow cytometric vasp phosphorylation is an independent predictor of death and cardiovascular death in unselected patients undergoing PCI. Am J Cardiol 2009;104(Suppl. 1):171D | C |
| Okada K, Tsukahara K, Endo T, Hibi K, Uchino K, Umemura S, et al. Carriage of reduced-function CYP2C19 allele is an independent predictor of periprocedual myocardial infarction in patients with non ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2012;59(Suppl. 1):E528 | C |
| Oliveira DC, Silva RF, Silva DJ, Lima VC. Aspirin resistance: fact or fiction. Arq Bras Cardiol 2010;95:e91–4 | A |
| Oliver WC, Kroening BJ, Waldo S, Diegel R, Brommer C, Schroeder D, et al. Coagulation tests predict bleeding in the intensive care unit after cardiac surgery. Transfusion 2010;50:180A–1A | B, C, D |
| O’Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995;26:995–9 | C, D |
| Oshima S, Noda K, Fukushima H, Nakamura S, Taniguchi I, Kugimiya F, et al. Platelet reactivity after thienopyridine treatment: assessment with screen filtration pressure method and drug-eluting stent thrombosis. J Am Coll Cardiol 2010;55(Suppl. 1):A171 | C |
| Osmancik PP, Bednar F, Pavkova L, Tousek P, Stros P, Jirasek K. Higher platelet activity is present in patients with restenosis after percutaneous coronary intervention compared with patients with an occlusion of coronary artery bypass graft. Blood Coagul Fibrinolysis 2008;19:807–12 | C, D |
| Ozben B, Tanrikulu AM, Ozben T, Caymaz O. Aspirin resistance in hypertensive patients. J Clin Hypertens 2010;12:714–20 | D |
| Paikin J, Eikelboom JW, Brons S, Rokoss MJ, Valettas N, Velianou JL, et al. Distribution of response to clopidogrel therapy using vasodilator stimulated phosphoprotein assay in patients undergoing primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Can J Cardiol 2011;27(Suppl. 1):S182–3 | B, C |
| Paniccia R, Antonucci E, Maggini N, Romano E, Lucarini L, Rossi L, et al. Platelet reactivity in stable atherosclerotic disease patients on chronic antiplatelet treatment. J Thromb Haemost 2009;7:599–600 | D |
| Papathanasiou A, Goudevenos J, Tselepis AD. Resistance to aspirin and clopidogrel: possible mechanisms, laboratory investigation, and clinical significance. Hellenic J Cardiol 2007;48:352–63 | A |
| Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E, et al. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005;39:1013–18 | D |
| Park D-W, Kim Y-G, Park G-M, Hwang K-W, Kwon C-H, Jang J-Y, et al. Differential prognostic implication of a point-of-care platelet function test in acute coronary syndrome versus stable angina after percutaneous coronary intervention. Am J Cardiol 2012;109(Suppl. 1):77–8 | C |
| Park D-W, Kim Y-G, Park G-M, Hwang KW, Kwon CH, Jang JY, et al. Differential prognostic implication of a point-of-care platelet function test in patients with acute coronary syndrome versus stable angina and who undergoing percutaneous coronary intervention. Circulation 2011;124(Suppl. 1):A15095 | B, C |
| Park D-W, Lee S-W, Yun S-C, Song H-G, Ahn J-M, Lee J-Y, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011;58:2630–9 | C |
| Park JH, Kim JS, Ahn C-M, Hong SJ, Choi JW, Ahn KJ, et al. A prospective multi-center study exploring method of clopidogrel pre-treatment undergoing conventional coronary angiogram in angina patients. Am J Cardiol 2012;109(Suppl. 1):136S | C, D |
| Park KW, Jeon KH, Kang SH, Oh IY, Cho HJ, Lee HY, et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011;108:1556–63 | C |
| Parodi G, Bellandi B, Venditti F, Carrabba N, Valenti R, Migliorini A, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012;109:214–18 | C |
| Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215–23 | C |
| Parodi G, Said K, Elfaramawy A, Hassan M, Marcucci R, Bellandi B, et al. Effectiveness of bivalirudin therapy in patients with high residual platelet activity after clopidogrel loading dose in patients undergoing elective percutanous coronary intervention: Six-month results from the Antithrombotic Regimens and Outcome (ARNO) trial. J Am Coll Cardiol 2010;56(Suppl. 1):B28 | C |
| Pastor-Perez FJ, Rivera J, Hurtado JA, Navarro L, Ruiz-Nodar JM, Roldan V, et al. Residual platelet activation: too many methods for an accurate definition in clinical practice. Eur Heart J 2009;30:195 | D |
| Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710–13 | A |
| Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128–33 | C |
| Patti G, Nusca A. Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty. Circ J 2011;75:2050–1 | A |
| Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011;107:995–1000 | C |
| Payne DA, Jones CI, Hayes PD, Bell PRF, Goodal AH, Naylor AR. Effect of low-dose (75 mg) clopidogrel on platelet reactivity, ADP variability, and clopidogrel resistance when given before carotid surgery. The Vascular Society Yearbook 2005. London: The Vascular Society of Great Britain and Ireland; 2005. p. 48 | D |
| Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–5 | D |
| Peace AJ, Egan K, Kavanagh GF, Tedesco AF, Foley DP, Dicker P, et al. Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. J Thromb Haemost 2009;7:1941–3 | B, D |
| Perez de Prado A, Cuellas C, Diego A, de Miguel A, Fernandez-Vazquez F. Platelet reactivity and stent thrombosis: still some issues to solve. J Am Coll Cardiol 2009;54:666–7 | A |
| Perez de Prado A, Cuellas C, Diego A, de Miguel A, Samaniego B, Alonso-Orcajo N, et al. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2009;124:678–82 | C |
| Petr R, Motovska Z, Marinov L, Bilkova D, Widimsky P. Resistance to clopidogrel assessed by VASP phosphorylation is a negative prognostic factor in patients undergoing elective PCI for stable coronary artery disease: Analysis from laboratory substudy of Prague 8 trial. J Am Coll Cardiol 2010;55(Suppl. 1):A98 | C |
| Pham JP, Ueno M, Tello-Montoliu A, Ferreiro JL, Tomasello SD, Dharmashankar K, et al. Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. J Am Coll Cardiol 2011;58:1396–8 | A |
| Piedade PR, Gagliardi RJ, Damiani IT, Nassar Junior AP, Fuzaro MM, Sanvito WL. [Platelet aggregation test: application in the control of antiplatelet aggregation in the secondary prevention of stroke.] Arq Neuropsiquiatr 2003;61:764–7 | C |
| Pierri H, Wajngarten M, Chamone D, Giannini SD, Ramires JA, Bellotti G, et al. [Behavior of the platelet number and aggregation in elderly patients with coronary disease subjected to stress.] Arq Bras Cardiol 1988;51:451–3 | C, D |
| Pittens CA, Bouman HJ, van Werkum JW, ten Berg JM, Hackeng CM. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. J Thromb Haemost 2009;7:1929–32 | B, C, D |
| Pliutto AM. [Changes of certain indicators of blood coagulation in patients with coronary arteriosclerosis and hypertensive disease.] Lab Delo 1974;8:465–8 | B, C, D |
| Poston R, Gu J, Brown J, Gammie J, White C, Manchio J, et al. Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. J Cardiothorac Vasc Anesth 2005;19:11–18 | D |
| Poston R, Gu J, Manchio J, Lee A, Brown J, Gammie J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005;27:584–91 | D |
| Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122–30 | D |
| Poston RS, Gu J, White C, Jeudy J, Nie L, Brown J, et al. Perioperative management of aspirin resistance after off-pump coronary artery bypass grafting: possible role for aprotinin. Transfusion 2008;48(Suppl.):39S–46S | D |
| Postula M, Tarchalska-Krynska B, Filipiak KJ, Kosior D, Serafin A, Huczek Z, et al. Factors responsible for ‘aspirin resistance’ – can we identify them? Kardiol Pol 2010;68:403–11 | D |
| Poulsen TS, Kastrup A, Mickley H. Is aspirin resistance or female gender associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention? J Am Coll Cardiol 2005;45:635–6 | A |
| Poulsen TS, Kristensen SR, Atar D, Mickley H. A critical appraisal of the phenomenon of aspirin resistance: a review. Cardiology 2005;104:83–91 | A |
| Pouplard C, Blicq E, Regina S, De Labriolle A, Charbonnier B, Gruel Y. Relation between cytochrome P450 2C19 681 G>A polymorphism, platelet responsiveness to ADP and clinical outcome after elective percutaneous coronary intervention in patients treated with clopidogrel. J Thromb Haemost 2009;7:1054 | C |
| Powers ER, Fowler A, Thieling C, Diaz-Gonzales V, Devlin M, Fernandes V, et al. Point-of-care testing of Platelet Function at the time of percutaneous coronary intervention identifies patients at risk for early post-procedure ischemia. J Am Coll Cardiol 2009;53:A69 | D |
| Preisman S, Kogan A, Itzkovsky K, Leikin G, Raanani E. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg 2010;37:1367–74 | D |
| Preisman S, Kogan A, Itzkovsky K, Leikin G, Raanani E. The risk of postoperative bleeding in patients receiving clopidogrel can be predicted using modified bedside thromboelastography. Interact Cardiovasc Thorac Surg 2009;9:S107 | D |
| PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J 2001;141:402–9 | C |
| Price M, Lillie E, Angiolillo D, Teirstein P, Berger P, Tanguay JF, et al. Platelet reactivity on clopidogrel therapy and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent pharmacodynamic analysis of the GRAVITAS trial. Eur Heart J 2011;32:507–8 | B, C |
| Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132–7 | B, C |
| Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105. [Erratum published in JAMA 2011;305:2174. Note: Stillablower, Michael E (corrected to Stillabower, Michael E)] | C |
| Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992–1000 | C |
| Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339–43 | C |
| Price MJ. ‘A threshold of platelet reactivity for ischaemic events?’ and ‘The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of care VerifyNow P2Y12 assay’: reply. Eur Heart J 2008;29:2187 | A |
| Price MJ. Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention? The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:277–83 | A |
| Price MJ. The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:277–83. [Erratum published in Circ Cardiovasc Interv 2010;3:e18] | A |
| Prieto R, Martlnez-Selles M, Fernandez-Aviles F. Essential thrombocytemia and acute coronary syndrome: clinical profile and association with other thromboembolic events. Acute Card Care 2008;10:116–20 | D |
| Qayyum R, Kral BG, Yanek LR, Vaidya D, Nyquist PA, Mathias R, et al. Greater post-aspirin residual platelet aggregation is associated with increased risk of incident acute coronary syndromes in healthy individuals. Circulation 2011;124(Suppl. 1):A16658 | B |
| Qureshi H, Ahmed A, Dhillon JK. Evaluation of clinical and cost effectiveness of thromboelastography (TEG) in cardiac surgery. Transfus Altern Transfus Med 2010;11:38 | D |
| Rade JJ, Gluckman TJ, McLean RC, Thompson JB, Thiemann DR, Laws K, et al. Aspirin-insensitive platelet hyper-reactivity and thromboxane generation are independent risk factors for early vein graft occlusion after coronary artery bypass surgery. J Am Coll Cardiol 2009;53:A334 | D |
| Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004;2:2278–9 | D |
| Randall M, Storey RF, Venables GS, Gaines PA, Cleveland TJ. Variability in patient response to clopidogrel and effects on outcome from carotid stenting. J Neurol Neurosurg Psychiatry 2010;81:e69–70 | C, D |
| Range G, Thuaire C, Richard P, Chassaing S, Belle L, Cazaux P, et al. Clinical impact of response to both aspirin and clopidogrel in 1001 patients undergoing coronary stenting: the one-year results of the multicenter Verifrenchy study. Eur Heart J 2010;31:154 | D |
| Ranjadayalan K, Umachandran V, Timmis AD, Gutteridge CN. Platelet size and outcome after myocardial infarction. Lancet 1992;339:625 | B |
| Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011;91:123–9 | C |
| Ray MJ, Walters DL, Bett N, Cameron J, Wood P, Aroney C. Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention. Catheter Cardiovasc Interv 2004;62:150–4 | B, C |
| Reed GW, Cannon CP. Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J Am Coll Cardiol 2011;58:2640–1 | A |
| Ren Y, Chen Y, Zhao M, Chen J, Chen L. Comparative study of aspirin and clopidogrel in high risk ACS. Heart 2010;96:A142–3 | D |
| Ren YH, Yang TS, Wang Y, Gai LY, Liu HB, Chen L, et al. Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome. Chin Med J 2008;121:850–2 | D |
| Renaud S. Risk factors for coronary heart disease and platelet functions. Adv Exp Med Biol 1984;164:129–44 | A, B |
| Renda G, Sciartilli A, De Caterina R. Aspirin resistance. Haematologica 2003;88(Suppl. 4):43–9 | A |
| Reny J-L, Berdague P, Combescure C, Nolli S, Barazer I, Fabbro-Peray P, et al. High residual platelet reactivity assessed with specific and global tests in the ADRIE study: comparative predictive values for the recurrence of ischemic events. J Thromb Haemost 2011;9:720 | D |
| Reny J-L, Fontana P, Fabbro-Peray P, Laporte S, van Werkum JW, ten Berg JM, et al. Practical use and limitations of ADP aggregation testing to predict cardiovascular events: design and preliminary results of a meta-analysis on individual patients data. J Thromb Haemost 2011;9:337–8 | C |
| Reny JL, Quere I, de Moerloose P, Fontana P. Aspirin response variability assessed with the PFA-100 device. Thromb Haemost 2008;99:968–9 | A |
| Rha JH, Kim SR, Kim SH, Kim IG, Song CS, Choi YJ, et al. Relationships between laboratory antiplatelet resistance and clinical antiplatelet failure. Cerebrovasc Dis 2009;27:49 | D |
| Ricottini E, Patti G, Vizzi V, Nusca A, Grieco D, Pasceri V, et al. A heightened platelet response to clopidogrel by point-of-care testing predicts bleeding outcomes in patients undergoing percutaneous coronary intervention. Results of armyda-bleeds (antiplatelet therapy for reduction of myocardial damage during angioplasty-bleeding study). J Am Coll Cardiol 2011;57(Suppl. 1):E1631 | C |
| Rideg O, Komocsi A, Magyarlaki T, Tokes-Fuzesi M, Miseta A, Kovacs GL, et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 2011;12:1269–80 | C |
| Ripley AW, Narang J, Leitch S, Fifi J, Bennett H. Clopidogrel resistance in patients requiring endovascular neurological intervention. J Neurosurg Anesthesiol 2011;23:441 | C |
| Rodzynek JJ, Leautaud P, Martin T, Schoenfeld PL, Wettendorff P, Delcourt A. Detection of a procoagulant activity in acute ischaemic heart disease. Thromb Res 1984;33:355–60 | D |
| Rohatgi S, Aronow HD. Detection and management of aspirin resistance. Crit Pathw Cardiol 2004;3:177–83 | A |
| Romashov VP. [Comparative evaluation of thromboelastographic data and some biochemical indices in myocardial infarct and stenocardia patients during anticoagulant therapy.] Ter Arkh 1964;36:11–17 | B, D |
| Ronge R, Lindemann S, Gawaz M. Sex differences in platelet reactivity and response to aspirin therapy: Comment. Dtsch Med Wochenschr 2006;131:1990 | A |
| Rouvier J, Scazziota A, Altman R. Aspirin resistance. Circulation 2002;106:e200–1 | A |
| Ryan WL, Hakenkamp K. Variable response to aspirin measured by platelet aggregation and bleeding time. Lab Med 1991;22:197–202 | B, D |
| Ryu DS, Hong CK, Sim YS, Kim CH, Jung JY, Joo JY. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319–24 | D |
| Ryu J, Lee Y, Lee J, Choi J, Kim K, Chang S. Efficacy of high maintenance dose of clopidogrel to overcome high post treatment platelet P2Y12 reactivity after drug eluting coronary stent implantation. Eur Heart J 2010;31:976–7 | D |
| Saad AA, Abd Elsalam AM, Kamal GM, Abou El-Ezz NF, El-Hagracy RS. Effect of cytochrome P450 3A5 polymorphism on platelet reactivity after treatment with clopidogrel in patients scheduled for percutaneous coronary intervention. Egypt Heart J 2011;63:23–31 | C |
| Sacchi S, Curci G, Peduzzi M, Barbieri U, Piccinini L. Evaluation of platelet kinetics and some coagulation parameters in diabetic retinopathy. Panminerva Med 1981;23:21–4 | D |
| Sadic BO, Tanrikulu MA, Koc M, Ozben T, Caymaz O. Aspirin resistance in patients with chronic renal failure. Eur Heart J 2010;31:966 | D |
| Sahin DY, Koc M, Cayli M, Uysal OK, Karaarslan O, Kanadasi M, et al. [The frequency of aspirin resistance by a modified thrombelastography method and its relationship with clinical and laboratory parameters in patients with stable coronary artery disease.] Turk Kardiyol Dernegi Ars 2012;40:33–40 | D |
| Sairaku A, Nakano Y, Eno S, Hondo T, Matsuda K, Kisaka T, et al. Platelet function measured using a whole blood aggregometer can predict bleeding events. J Atheroscler Thromb 2011;18:16–23 | B, C |
| Salat A, Boehm D, Pulaki S, Murabito M, Berlakovich G, Kretschmer G, et al. Possibility of checking compliance and efficacy of antiaggregatory treatment following femoro-popliteal vein bypass surgery. Thromb Res 1998;89:91–5 | D |
| Saleh N, Hansson LO, Kohut M, Nilsson T, Tornvall P. Platelet function and myocardial injury during percutaneous coronary intervention. J Thromb Thrombolysis 2002;13:69–73 | D |
| Sambu N, Dent H, Warner T, Englyst N, Leadbeater P, Hobson A, et al. Stopping clopidogrel 1 year after drug-eluting stent (DES) implantation: is it safe? J Am Coll Cardiol 2011;58(Suppl. 1):B41 | D |
| Sambu N, Radhakrishnan A, Dent H, Calver A, Corbett S, Gray H, et al. The clopidogrel resistance in stent thrombosis (CREST) registry: the case for personalized antiplatelet therapy? J Am Coll Cardiol 2011;58(Suppl. 1):B23 | D |
| Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002;90:893–5 | D |
| Sano K, Sugamata W, Deyama J, Uematsu M, Fujioka D, Nakamura T, et al. Usefulness of platelet retention assay for diagnosing acute coronary syndromes and predicting clinical outcome in patients with chest pain and/or shortness of breath. Circulation 2011;124(Suppl. 1):A9446 | B, C |
| Sano T, Yamazaki H. [Progress in blood platelet function tests and anticipation of thrombosis.] Nippon Rinsho 1978;36:3836–41 | A |
| Sansalvador V, Ezcurdia I. [Thromboelastographic study of the blood coagulation during the postoperative and postinfarct periods.] Rev Clin Esp 1964;92:185–8 | B, C, D |
| Saraf S, Bensalha I, Gorog DA. Antiplatelet resistance – does it exist and how to measure it? Clin Med Cardiol 2009;3:77–91 | A |
| Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010;55:2107–15 | C |
| Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, et al. Impact of calcium channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug eluting stenting. J Am Coll Cardiol 2011;57(Suppl. 1):E1913 | B, C |
| Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605–10 | C |
| Sardella G, Calcagno S, De Carlo C, Pennacchi M, Placentino F, Stio R, et al. Pharmacodynamic effects of switching therapy in PCI patients with high on treatment platelet reactivity and genotype variation: high clopidogrel dose versus prasugrel (reset trial). J Am Coll Cardiol 2012;59(Suppl. 1):E6 | C |
| Sardi G, Zaheeruddin S, Pakala R, Carnicero AL, Torguson R, Badr S, et al. Does on-treatment platelet reactivity testing before coronary artery bypass surgery have a value in predicting in-hospital major bleeding? J Am Coll Cardiol 2012;59(Suppl. 1):E261 | C |
| Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007;109:621–7 | C, D |
| Sarode R, Frenkel E. And, more on: assessing aspirin responsiveness using the VerifyNow aspirin assay. Thromb Res 2008;121:587–8 | A |
| Saunders J, Nambi V, Kimball KT, Virani SS, Morrisett JD, Lumsden AB, et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg 2011;53:668–75 | D |
| Saunders JT, Nambi V, Virani S, Yang E, Bergeron A, Athamneh H, et al. Twelve month persistence of poor response to aspirin in patients with peripheral arterial disease enrolled in the effect of lipid modification on peripheral arterial disease after endovascular intervention trial (ELIMIT). J Am Coll Cardiol 2010;55(Suppl. 1):A155 | D |
| Scalone G, Coviello I, Barone L, Battipaglia I, Aurigemma C, Careri G, et al. Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction. Thromb Res 2011;128:174–8 | C, D |
| Schaefer A, Flierl U, Seydelmann N, Bauersachs J. Impaired P2Y12 inhibition contributes to increased cardiovascular events following prehospital administration of clopidogrel in patients with ST elevation myocardial infarction. Eur Heart J Suppl 2010;12:F52–3 | C |
| Schafer A, Bonz AW, Eigenthaler M, Bauersachs J. Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function? Thromb Haemost 2007;97:862–5 | A |
| Schafer A, Flierl U, Kossler J, Seydelmann N, Kobsar A, Stork S, et al. Early determination of clopidogrel responsiveness by platelet reactivity index identifies patients at risk for cardiovascular events after myocardial infarction. Thromb Haemost 2011;106:141–8 | C |
| Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J 2006;27:2900–1 | A |
| Scheinowitz M, Slottow TLP, Pakala R, Baffour R, Bonello L, Torguson R, et al. Elevated circulating endothelial progenitor cells in stent thrombosis patients is not correlated with platelet reactivity index. J Am Coll Cardiol 2009;53:A13 | B, C |
| Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421–3 | C |
| Schneider DJ. On defining aspirin resistance. J Am Coll Cardiol 2005;46:1710–11 | A |
| Schreiber TL, Macina G, Bunnell P, Tenney RD, McNulty A, Kikel M, et al. Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms. Am Heart J 1990;120:248–55 | C |
| Schror K, Huber K, Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin. Biomarkers Med 2011;5:31–42 | A |
| Schror K. What is aspirin resistance? Br J Cardiol 2010;17(Suppl. 1):S5–7 | A |
| Schulz S, Sibbing D, Braun S, Morath T, Mehilli J, Massberg S, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J 2010;160:355–61 | C |
| Schulz S, Sibbing D, Morath T, von Beckerath N, Mehilli J, Byrne RA, et al. Does platelet reactivity to clopidogrel effect restenosis after DES implantation? Eur Heart J 2009;30:199 | C |
| Schwartz MB, Hawiger J, Timmons S, Friesinger GC. Platelet aggregates in ischemic heart disease. Thromb Haemost 1980;43:185–8 | B |
| Schwonberg J, Linnemann B, Toennes SW, Mani H, Lindhoff-Last E. Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease – a prospective study. J Thromb Haemost 2009;7:897 | B |
| Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, et al. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes (OPUS-TIMI 16) trial. J Thromb Thrombolysis 2006;22:95–102 | C |
| Seidel H, Rahman MM, Scharf RE. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie 2011;31:41–51 | A |
| Selvaraj CL, Van De Graaff EJ, Campbell CL, Abels BS, Marshall JP, Steinhubl SR. Point-of-care determination of baseline platelet function as a predictor of clinical outcomes in patients who present to the emergency department with chest pain. J Thromb Thrombolysis 2004;18:109–15 | C |
| Serebruany V, McKenzie M, Meister A, Fuzaylov S, Gurbel P, Atar D, et al. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT trial). Eur J Heart Fail 2002;4:461–7 | C, D |
| Serebruany V. Lack of outcome benefit and clopidogrel ‘resistance.’ The TRITON trial challenge. Thromb Haemost 2010;103:415–18 | A |
| Serebruany VL, Goto S. The challenge of monitoring platelet response after clopidogrel. Eur Heart J 2008;29:2833–4 | A |
| Serebruany VL, McKenzie ME, Meister AF, Fuzaylov SY, Gurbel PA, Atar D, et al. Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure. Pathophysiol Haemost Thromb 2002;32:8–15 | D |
| Sevcikova H, Vojacek J, Bis J, Sevcik R, Maly J, Pecka M, et al. Good short-term but not long-term reproducibility of the antiplatelet efficacy laboratory assessment. Clin Appl Thromb Hemost 2012;18:174–80 | D |
| Shalaev SV. [Development of myocardial infarction in aspirin-treated unstable angina pectoris. Repeated studies of platelet aggregation and of the thromboxane-prostacyclin system.] Kardiologiia 1992;32:27–30 | D |
| Shal’nov AI. [Ischemic heart disease and blood coagulation (data on the epidemiological examination of men 40–59 years of age by thrombelastography).] Ter Arkh 1981;53:41–6 | C, D |
| Shantsila E, Lip GY. Beyond glucose levels in diabetic patients with coronary artery disease: platelet activity and non-responsiveness to antiplatelet therapy. Thromb Haemost 2008;100:7–8 | A |
| Shantsila E, Watson T, Lip GY. Aspirin resistance: what, why and when? Thromb Res 2007;119:551–4 | A |
| Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009;5:965–72 | A |
| Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD. Evolving role of platelet function testing in coronary artery interventions. Vasc Health Risk Manag 2012;8:65–75 | A |
| Sharma S, Moffat D, Christopoulous C, Klonizakis M, Wellstead D, Farrington K, et al. Global thrombotic status predicts cardiovascular events in end-stage renal failure. Eur Heart J 2010;31:971 | B, C |
| Sharma V, Kaul S, Al-Hazzani A, Prabha TS, Rao PPKM, Dadheech S, et al. Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. J Neurol Sci 2012;315:72–6 | C |
| Sharp DS, Ben-Shlomo Y, Beswick AD, Andrew ME, Elwood PC. Platelet aggregation in whole blood is a paradoxical predictor of ischaemic stroke: Caerphilly prospective study revisited. Platelets 2005;16:320–8 | C |
| Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000;35:300–7 | D |
| Shen J, Zhang RY, Zhang Q. [Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina.] Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih 2008;36:807–11 | D |
| Shi ZW. [Aspirin resistant concept gives no guide to clinical application.] Chung-Hua Nei Ko Tsa Chih 2008;47:269–71 | A |
| Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002;89:331–3 | B, D |
| Shimomura H, Hokimoto S, Ogawa H. Clinical outcomes following coronary stenting in Japanese patients with and without proton pump inhibitor. J Am Coll Cardiol 2010;55(Suppl. 1):A52 | C |
| Sholokhova GI, Iakovleva IM. [Thromboelastogram in ischemic heart disease.] Kardiologiia 1973;13:130–2 | B, C, D |
| Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849–56 | C |
| Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – fact and fiction. Thromb Haemost 2011;106:191–202 | A |
| Sibbing D, Byrne RA, Kastrati A. Role of platelet function testing in clinical practice: current concepts and future perspectives. Curr Drug Targets 2011;12:1836–47 | A |
| Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512–18 | C |
| Sibbing D, Mayer K, Bernlochner I, Morath T, Jaitner J, Haase U, et al. Platelet function testing guided use of prasugrel in patients with high on-clopidogrel treatment platelet reactivity reduces the risk of early stent thrombosis. J Am Coll Cardiol 2012;59(Suppl. 1):E265 | C |
| Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010;103:151–9 | C |
| Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250–6 | C |
| Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregation and association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. Eur Heart J 2010;31:147 | B, C |
| Sibbing D, Taubert D, Schomig A, Kastrati A, von Beckerath N. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008;6:1230–2 | C, D |
| Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost 2006;4:2566–8 | C |
| Siegemund A, Korner I, Scholz U. Monitoring of antiplatelet agents – necessary in patients with cardiovascular diseases? J Thromb Haemost 2009;7:877 | D |
| Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly). J Am Geriatr Soc 1994;42:643–7 | B |
| Siller-Matula J, Delle KG, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping versus genotyping for prediction of adverse events in clopidogrel non-responders. J Kardiol 2011;18:189 | B, C |
| Siller-Matula JM, Christ G, Lang IM, le-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010;8:351–9 | C |
| Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557–63 | C |
| Siller-Matula JM, le-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012;10:529–42 | C |
| Siller-Matula JM, le-Karth G, Neunteufl T, Lang I, Kozinski M, Kubica J, et al. Phenotyping versus genotyping for prediction of adverse events in clopidogrel non-responders. Eur Heart J 2011;32:172 | B, C |
| Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994;89:596–603 | C, D |
| Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76–81 | C |
| Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med 2011;26:1336–44 | C |
| Singh A, Feit F, Bangalore S. Does triple therapy with cilostazol decrease platelet reactivity in patients undergoing percutaneous coronary intervention? A meta analysis of randomized clinical trials. J Am Coll Cardiol 2012;59(Suppl. 1):E527 | C |
| Singh A, Gupta OP, Sangha HK. Platelet function tests in acute myocardial infarction. Indian Heart J 1980;32:25–9 | B, D |
| Singh M, Shah T, Singh P, Adigopula S, Kodumuri V, Molnar J, et al. Platelet function tests predict a relationship between on-treatment platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention. Circulation 2011;124(Suppl. 1):A12086 | B, C |
| Singh S, Kothari SS, Bahl VK. Aspirin resistance: myth or reality? Indian Heart J 2003;55:217–22 | A |
| Smit JJJ, van Werkum JW, Heestermans AACM, Postma S, Hermanides RS, Dill T, et al. Insufficient platelet aggregation inhibition by pre-hospital clopidogrel alone vs additional high dose Tirofiban in patients with acute STEMI undergoing primary PCI resulting in worse clinical outcome. Eur Heart J 2009;30:193–4 | B |
| Smith JP, Haddad EV, Boutaud O, Oram DA, Blakemore DL, Chen QX, et al. Metabolic syndrome associates with resistance to aspirin in patients with coronary artery disease. Circulation 2009;120:S1033 | D |
| Smith PS. Who can resist aspirin? Nursing 2005;35:20 | A |
| Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981;48:395–402 | B, C, D |
| Smout J, Cleanthis M, Stansby G. Comment on ‘hyperresponsiveness of platelets in ischemic stroke’ by Fateh-Moghadam et al.
Thromb Haemost 2008;99:239 | A |
| Smout J, Stansby G. Aspirin resistance. Br J Surg 2002;89:4–5 | A |
| Snoep JD, Eikenboom JCJ, Zwaginga JJ, Roest M, Patrono C, Rocca B, et al. Platelet reactivity and recurrent cardiovascular events in patients with stable cardiovascular disease using aspirin: a head-to-head comparison of different tests. J Thromb Haemost 2011;9:16 | D |
| Snoep JD, Hovens MMC, Eikenboom JCJ, Van Der Bom JG, Huisman MV. Is aspirin resistance due to noncompliance? – reply. Arch Intern Med 2008;168:550 | A |
| Snoep JD, Hovens MMC, Eikenboom JCJ, Van Der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221–31 | C |
| Snoep JD, Roest M, Barendrecht A, Rosendaal FR, Van Der Bom JG. High platelet reactivity and the risk of myocardial infarction in young women. J Thromb Haemost 2009;7:275 | D |
| Sobol AB, Selmaj K, Mochecka A, Kumor A, Loba J. Aspirin responsiveness in ischemic stroke patients in relation to diabetes mellitus, lipid and hemostatic profile. Adv Clin Exp Med 2010;19:593–9 | D |
| Soffer D, Moussa I, Karatepe M, Harjai KJ, Boura J, Dixon SR, et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 2003;91:872–5 | C, D |
| Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010;103:841–8 | C |
| Mayo Clinic. Some people are resistant to aspirin’s protective effects. Mayo Clin Health Lett 2004;22:4 | A |
| Song T-J, Lee J-B, Suh S-H, Lee K-Y. The influence of anti-platelet resistance for the development of silent ischemia after carotid artery stenting. Int J Stroke 2010;5:162 | D |
| SoRelle R. Resisting aspirin. Circulation 2002;105:e9094–5 | A |
| Sorensen EN, Snyder TA, Lindsay MJ, Moainie SL, Feller ED, Griffith BP. Seven-fold stroke reduction in Ventricular-Assist Device (VAD) patients with titrated antiplatelet therapy. J Heart Lung Transplant 2009;28(Suppl. 1):S154 | C |
| Steinhubl SR, Campbell CL. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 2005;3:665–9 | A |
| Steinhubl SR, Varanasi JS, Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;42:1336–7. [Erratum published in J Am Coll Cardiol 2004;43:154. Note: Varinasi JS (corrected to Varanasi JS)] | A |
| Steinhubl SR, Varanasi JS, Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;42:1336. [Erratum published in J Am Coll Cardiol 2004;43:154] | A |
| Steinhubl SR. The illusion of ‘optimal’ platelet inhibition. JACC Cardiovasc Interv 2012;5:278–80 | A |
| Stiefelhagen P, Krasopoulos G. Aspirin resistance increases cardiovascular risk. MMW-Fortschr Med 2009;151:27 | A |
| Strano A, Davi G. Platelet function tests and coronary heart disease. Adv Exp Med Biol 1984;164:31–47 | A |
| Suchkova EN. [Blood coagulation capacity in patients with diabetes mellitus according to biochemical and thromboelastographic data.] Ter Arkh 1965;37:80–5 | C, D |
| Sudkamp M, Mehlhorn U, Reza RM, Hekmat K, Easo J, Geissler HJ, et al. Cardiopulmonary bypass copolymer surface modification reduces neither blood loss nor transfusions in coronary artery surgery. Thorac Cardiovasc Surg 2002;50:5–10 | C, D |
| Suh J-W, Kim C-H, Oh I-Y, Yoon C-H, Cho Y-S, Youn T-J, et al. The effect of tailored antiplatelet therapeutic strategy during percutaneous coronary intervention on periprocedural myonecrosis in diabetic patients: insights from the DM-verifynow study. J Am Coll Cardiol 2012;59(Suppl. 1):E1532 | C |
| Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280–9 | C |
| Sung JK, Yoon YJ, Lee NS, Lee JW, Kim J-Y, Lee SH, et al. The effect of clopidogrel low-responsiveness assessed by VerifyNow P2Y12 assay on thrombotic events after implantation of drug-eluting stent. J Am Coll Cardiol 2010;55(Suppl. 1):A206 | C |
| Suslina ZA, Tanashian MM, Domashenko MA. [Resistance to antiplatelet drugs in patients with cerebrovascular disorders.] Vestn Ross Akad Med Nauk 2011;7:3–8 | A |
| Szczeklik A, Musial J, Undas A. Reasons for resistance to aspirin in cardiovascular disease. Circulation 2002;106:e181–2 | A |
| Szczeklik A, Undas A. More on: aspirin resistance. J Thromb Haemost 2004;2:1489 | A |
| Szczeklik A. Reasons for aspirin resistance. Thromb Haemost 2011;105:1124 | A |
| Szymezak J, Moreau C, Loriot MA, Durand E, Van Viet H, Desnos M, et al. High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment. Thromb Res 2011;128:92–5 | C |
| Takatsu Y, Yui Y, Hattori R, Sakaguchi K, Susawa T, Yui N, et al. Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction – their relation to coronary patency. Jpn Circ J 1988;52:314–20 | B |
| Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets 2004;15:325–32 | D |
| Tanboga IH, Tokgoz HC, Can MM, Bezgin T, Turkyilmaz E, Akgun T, et al. The polymorphisms of CYP2C19, CYP3A5 and CYP2C9 enzymes in relation to platelet response to clopidogrel as assessed by multiplate analyser and long-term clinical outcome. Eur Heart J 2010;31:1017–18 | B |
| Tanigawa T, Nishikawa M, Kitai T, Ueda Y, Okinaka T, Makino K, et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 2000;85:1054–9 | D |
| Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Aspirin resistance in patients with chronic renal failure. J Nephrol 2011;24:636–46 | D |
| Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705–9 | D |
| Tantry US, Jeong Y-H, Navarese EP, Gurbel PA. Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y12 inhibitor therapeutic window. JACC Cardiovasc Interv 2012;5:290–2 | A |
| Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009;52:141–52 | A |
| Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010;21:360–7 | D |
| Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011;8:572–9 | A |
| Taomoto K, Ohnishi H, Kuga Y, Nakashima K, Kodama Y, Kubota H, et al. Clinical outcome and platelet function of acute stroke by global thrombosis test (GTT) after t-PA therapy. J Thromb Haemost 2011;9:84 | B, C, D |
| Tarjan J, Salamon A, Jager R, Poor F, Barczi V, Dinnyes J, et al. [The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis.] Orvosi Hetil 1999;140:2339–43 | D |
| Tarzia V, Paolini C, Bottio T, Rizzoli G, Spiezia L, Dal LC, et al. Perioperative hemostasis and bleeding risk in double-antiplatelet high risk patients undergoing coronary revascularization procedure. A prospective controlled study. Eur Heart J 2010;31:62 | C, D |
| Tefferi A. Overcoming ‘aspirin resistance’ in MPN. Blood 2012;119:3377–8 | A |
| Tello-Montoliu A, Jover E, Marin F, Bernal A, Lozano ML, Sanchez-Vega B, et al. Influence of CYP2C19 polymorphisms in on-treatment platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Eur Heart J 2011;32:264 | C |
| Tello-Montoliu A, Jover E, Marin F, Bernal A, Lozano ML, Sanchez-Vega B, et al. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) 2012;65:219–26 | C |
| ten Berg JM. Error in a study of the comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary artery stent implantation. JAMA 2011;305:2172–3. [Erratum for JAMA 2010;303:754–62] | A |
| Thani KB, Ilapakurti M, Ang L, Prasad A, Palakodeti V, Mahmud E. Increased incidence of peri-procedural myocardial infarction in patients pre-treated with clopidogrel and undergoing percutaneous coronary intervention: role of fibrinogen and platelet reactivity. Catheter Cardiovasc Interv 2010;75:S59 | B |
| Theakos N, Dedeilias P, Argiriou M, Roussakis A, Patronis M, Bolos K. Postoperative aspirin and clopidogrel resistance in patients submitted to on-pump coronary artery bypass surgery. Interact Cardiovasc Thorac Surg 2009;9:S106 | D |
| Thomas M, Wijeyeratne Y, May J, Fox S, Heptinstall S. P-selectin is associated with subsequent atherothrombotic events in patients with recent acute coronary syndromes treated with clopidogrel. J Thromb Haemost 2011;9:743 | C |
| Tidiane AM, Ghenim R, Bongard V, Boudou N, Dumonteil N, Hammami N, et al. Assessment of dual antiplatelet responsiveness with the point-of-care device verifynow after percutaneous coronary intervention in elderly patients (> 75 years). J Am Coll Cardiol 2010;55(Suppl. 1):A171 | D |
| Tidjane AM, Ghenim R, Bongard V, Boudou N, Dumonteil N, Hammami N, et al. Natural history of dual anti-platelet responsiveness after angioplasty in elderly patients. Arch Cardiovasc Dis Suppl 2010;2:15 | D |
| Tirosh-Wagner T, Strauss T, Rubinshtein M, Tamarin I, Mishaly D, Paret G, et al. Point of care testing in children undergoing cardiopulmonary bypass. Pediatr Blood Cancer 2011;56:794–8 | B |
| Tobin WO, Kinsella JA, Collins DR, Coughlan T, O’Neill D, Egan B, et al. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. Br J Haematol 2011;152:640–7 | D |
| Tobin WO, Kinsella JA, Collins DR, Coughlan T, O’Neill D, Feeley TM, et al. Enhanced ex vivo inhibition of platelet function after addition of dipyridamole to aspirin in ischaemic cerebrovascular disease – interim results from the trinity antiplatelet responsiveness study. J Neurol Neurosurg Psychiatry 2009;80:e1 | D |
| Tobin WO, Kinsella JA, Murphy RP, Collins DR, Coughlan T, O’Neill D, et al. Circulating reticulated platelets influence the ex vivo response to aspirin, but not dipyridamole or clopidogrel, in the early phase after TIA or ischaemic stroke – initial results from the trinity antiplatelet responsiveness (TRAP) study. Cerebrovasc Dis 2011;31:142 | D |
| Tobin WO, Kinsella JA, Murphy RP, Collins DR, Coughlan T, O’Neill D, et al. Novel longitudinal definitions of aspirin and clopidogrel ‘non-responsiveness’ on the PFA-100: results from the trinity antiplatelet responsiveness (TRAP) study. Cerebrovasc Dis 2011;31:139 | D |
| Topcuoglu MA, Arsava EM, Ay H. Antiplatelet resistance in stroke. Expert Rev Neurother 2011;11:251–63 | A |
| Tousek P, Osmancik P, Paulu P, Kocka V, Widimsky P. Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: a single-center pilot randomised study. Int J Cardiol 2011;150:231–2 | C |
| Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925–34 | C |
| Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, et al. No association of paraoxonase-1 Q192R genotype with antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Br J Clin Pharmacol 2011;72:8 | B |
| Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011;4:429–36 | C |
| Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008;99:174–81 | C |
| Trenk D, Hochholzer W, Valina CM, Stratz C, Bestehorn H-P, Buettner HJ, et al. Clinical events in patients undergoing percutaneous coronary intervention with bare-metal stenting after discontinuation of clopidogrel. Eur Heart J 2010;31:965 | B |
| Trenk D, Hochholzer W, Valina CM, Stratz C, Bestehorn HP, Buttner HJ, et al. Increased incidence of clinical events in patients undergoing percutaneous coronary intervention with baremetal stenting after discontinuation of clopidogrel. Br J Clin Pharmacol 2010;70:5 | B, C |
| Trenk D, Neumann FJ. Aspirin resistance an underestimated risk in patients with drug-eluting stents? J Am Coll Cardiol 2008;52:740–2 | A |
| Tschopp TB, Zucker MB. Platelet function tests in disease. Annu Rev Med 1973;24:1–18 | A |
| Tsiaousis GZ, Zairis MN, Patsourakos N, Makrygiannis S, Vogiatzidis K, Gougourela E, et al. Oral proton pump inhibitors and their impact on the effectiveness of dual anti-platelet therapy during the first year after elective coronary stenting. J Am Coll Cardiol 2009;53:A335 | C |
| Tsimikas S, Leibundgut G. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: en attendant Godot. JACC Cardiovasc Interv 2010;3:657–9 | A |
| Tsui PT, Lau CL, Lo YK, Chan NY, Wu CW, Choy CC, et al. Low platelet responsiveness to clopidogrel is related to target lesion revascularization in Chinese. Am J Cardiol 2008;105(Suppl. 1):25B | C, D |
| Tsui PT, Lau CL, Lo YK, Mok NS, Lau ST. Effectiveness of clopidogrel in Chinese. Int J Cardiol 2011;147:S11 | B, C |
| Tsukahara K, Kimura K, Ebina T, Kosuge M, Hibi K, Iwahashi N, et al. The relationship between high on-treatment platelet reactivity and rapid angiographic progression of non-culprit coronary lesions in patients with acute coronary syndromes. J Am Coll Cardiol 2011;57(Suppl. 1):E928 | C |
| Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010;74:679–85 | C |
| Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, et al. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol 2004;94:1406–10 | A |
| Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994;25:1547–51 | D |
| Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 2011;4:905–12 | D |
| Ulehlova J, Slavik L, Krcova V, Galuszka J, Vaclavik J. Platelet gene polymorphisms related to acute myocardial infarction in young patients. J Thromb Haemost 2011;9:343 | D |
| Undas A, Placzkiewicz-Jankowska E, Zielinski L, Tracz W. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. Thromb Haemost 2007;97:1056–8 | D |
| Valenti R, Migliorini A, Giuliani G, Parodi G, Buonamici P, Cerisano G, et al. Nonresponsiveness to clopidogrel and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Am J Cardiol 2009;104(Suppl. 1):97D | C |
| Valenti R, Migliorini A, Parodi G, Marcucci R, Buonamici P, Cerisano G, et al. Diabetes mellitus requiring insulin and high residual platelet reactivity after clopidogrel loading dose are predictors of long-term clinical outcome in patients with acute coronary syndrome: the RECLOSE2-ACS diabetes mellitus substudy. J Am Coll Cardiol 2011;58(Suppl. 1):B114 | C |
| Valenti R, Parodi G, Antoniucci D. High residual platelet reactivity and thrombotic events – reply. JAMA 2011;306:2561–2 | A, B, C |
| Valenti R, Parodi G, Migliorini A, Marcucci R, Buonamici P, Cerisano G, et al. The impact of high residual platelet reactivity after clopidogrel loading on long-term clinical outcome of patients with acute coronary syndromes receiving an invasive treatment: the RECLOSE 2-ACS trial. J Am Coll Cardiol 2011;58(Suppl. 1):B16 | C |
| Valenti R, Vergara R, Migliorini A, Carrabba N, Cerisano G, Parodi G, et al. High residual platelet reactivity after clopidogrel loading and clinical outcome after drug-eluting stenting for chronic total occlusion. G Ital Cardiol 2011;12(Suppl. 1):36S | C |
| Valgimigli M, Campo G, Ferrari R, de Cesare N, Meliga E, Vranckx P, et al. Response to letter regarding article, ‘intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study’. Circulation 2010;121:e236 | A |
| Valles J, Santos MT, Fuset MP, Moscardo A, Ruano M, Perez F, et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007;99:19–25 | D |
| van Werkum JW, Hackeng CM, Smit J-J, van’t Hof AWJ, Verheugt FWA, ten Berg JM. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008;4:33–55 | A |
| van Werkum JW, Kleibeuker M, Mieremet N, ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007;5:884–6 | C, D |
| van Werkum JW, ten Berg JM. Platelet reactivity as a risk-factor for stent thrombosis: can this be one of the currently available appropriate methods to determine platelet reactivity? Eurointervention 2008;4(Suppl. C):11–16 | A |
| van Werkum JW, Topcu Y, Postma S, Kelder JC, Hackeng CM, ten Berg JM, et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008;99:637–9 | C, D |
| van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006;4:2516–18 | C, D |
| van Werkum JW, van der Stelt CA, Seesing TH, ten Berg JM, Hackeng CM. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 2007;5:881–3 | C, D |
| Varanasi JS, Steinhubl SR. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:e144–5 | A |
| Vatakencherry A, Narang J, Kim J, Wasnick J, Langer D, Bennett H. Aspirin resistance in neurosurgical vascular bypass procedures. J Neurosurg Anesthesiol 2008;20:294–5 | D |
| Verschuren JJ, Boden H, Wessels JA, Guchelaar H-J, Schalij MJ, Jukema JW. Platelet pharmacogenetics in common clinical practice. Circulation 2011;124(Suppl. 1):A12668 | C |
| Vila PM, Zafar MU, Badimon JJ. Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. Platelets 2009;20:531–8 | A |
| Violi F, Pignatelli P, Basili S. Letter by Violi et al. regarding article, ‘Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization’. Circulation 2010;122:e429 | A |
| Violi F, Pignatelli P. Aspirin resistance. Lancet 2006;367:2059–60 | A |
| Violi F, Pignatelli P. The need for a consistent definition of ‘aspirin resistance’. J Thromb Haemost 2006;4:1618–19 | A |
| Vlachojannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hell J Cardiol 2011;52:236–45 | A |
| Volenti R, Vergara R, Migliorini A, Carrabba N, Cerisano G, Parodi G, et al. High residual platelet reactivity after clopidogrel loading and clinical outcome after drug-eluting stenting for chronic total occlusion. J Am Coll Cardiol 2010;56(Suppl. 1):B49 | C |
| von Kaulla E, von Kaulla KN. [Detection of a thrombotic tendency by means of coagulation tests (author’s transl).] MMW Munch Med Wochenschr 1974;116:1387–96 | A |
| von Pape KW, Strupp G, Bonzel T, Bohner J. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 2005;94:889–91 | D |
| Von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays: PFA-100 and Multiplate. Hamostaseologie 2007;27:155–60 | D |
| Voora D, Horton J, Shah SH, Shaw LK, Newby LK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J 2011;162:166–72 | C |
| Waheed R, Lockhart MK, Gopinath D, Mohammed A, Wazir S, Quealy K, et al. Prevalence of aspirin resistance in patients with peripheral arterial disease. Vasc Med 2010;15:143–4 | D |
| Walters TK, Mitchell DC, Wood RF. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 1993;80:1266–8 | D |
| Wang B. Progress of aspirin resistance. Chin J Cerebrovasc Dis 2010;7:553–6 | A |
| Wang L, Wang X, Chen F. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs R D 2010;10:219–24 | C |
| Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, et al. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation 2009;119:2454–62 | C |
| Wang X-D, Zhang D-F, Liu X-B, Lai Y, Qi W-G, Luo Y, et al. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. Eur J Intern Med 2012;23:48–53 | C |
| Wang XD, Zhang DF, Zhuang SW, Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011;34:332–8 | C |
| Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009;124:46–51 | C |
| Warner TD, Mitchell JA, Kirkby NS. Short thromboelastography and the identification of high platelet reactivity while on and off therapy. Heart 2012;98:679–80 | A |
| Wasowicz M, McCluskey SA, Wijeysundera DN, Yau TM, Meinri M, Beattie WS, et al. The incremental value of thrombelastography for prediction of excessive blood loss after cardiac surgery: an observational study. Anesth Analg 2010;111:331–8 | C |
| Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900 | A |
| Weber ZA, Rodgers PT. The clinical significance of the interaction between proton pump inhibitors and clopidogrel. J Pharm Technol 2010;26:22–6 | B, C |
| Welsby IJ, Jiao K, Ortel TL, Brudney CS, Roche AM, nett-Guerrero E, et al. The kaolin-a. J Cardiothorac Vasc Anesth 2006;20:531–5 | C, D |
| Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;46:CS5–6 | D |
| Wientong P, Jongjarornprasert W, Panomvana D. Platelet aggregation and serum thromboxane B2 level after taking 60 mg/day of aspirin in type 2 diabetic Thai patients. Int J Pharm Pharm Sci 2011;3(Suppl. 3):47–50 | D |
| Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2005;25:2661–6 | C |
| Winckers K, Poenitz V, van Oerle R, Noordermeer K, Ten CH, Nilsen DWT. A case control study on platelet response to antiplatelet therapy in survivors of late stent thrombosis. J Thromb Haemost 2009;7(S2):649 | D |
| Windelov NA, Welling KL, Ostrowski SR, Johansson PI. The prognostic value of thrombelastography in identifying neurosurgical patients with worse prognosis. Blood Coagul Fibrinolysis 2011;22:416–19 | B, C |
| Wong S, Appleberg M, Lewis DR. Antiplatelet therapy in peripheral occlusive arterial disease. ANZ J Surg 2006;76:364–72 | C |
| Wong S, Appleberg M, Ward CM, Lewis DR. Review finds further work is required to define and assess the incidence of aspirin resistance. Evid Based Cardiovasc Med 2004;8:267 | A |
| Wong S, Morel-Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 2006;95:1042–3 | D |
| Woo JS, Kim W, Lee JH, Choi E-Y, Jang WS, Kim GS. Association of platelet reactivity and endothelial function and anti-inflammatory effects in patients with stable coronary artery disease. Am J Cardiol 2012;109(Suppl. 1):77S | C, D |
| Woo KS, Kim BR, Kim JE, Goh RY, Yu LH, Kim MH, et al. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Kor J Lab Med 2010;30:460–8 | D |
| Worrall A, Armesilla A, Norell M, Khogali S, Cusack M, Smallwood A, et al. The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the verifynow P2Y12 near-patient testing device in patients undergoing coronary angiography. Eur Heart J 2009;30:327 | C |
| Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010;3:828–35 | D |
| Xanthopoulou I, Tsigkas G, Damelou A, Theodoropoulos KC, Kassimis G, Chouchoulis K, et al. Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST elevation myocardial infarction patients. J Am Coll Cardiol 2012;59(Suppl. 1):E485 | B |
| Xu Z-H, Jiao J-R, Yang R, Luo B-Y, Wang X-F, Wu F. Aspirin resistance: clinical significance and genetic polymorphism. J Int Med Res 2012;40:282–92 | B |
| Yahia AM, Latorre J, Gordon V, Whapham J, Malek A, Fessler RD. Thromboembolic events associated with Neuroform stent in endovascular treatment of intracranial aneurysms. J Neuroimaging 2010;20:113–17 | C |
| Yamaguchi Y, Abe T, Sato Y, Moriki T, Murata M. Point-of-care assessment after clopidogrel treatment predicts clinical outcomes of patients with cardiovascular disease: a meta-analysis of six studies. J Thromb Haemost 2011;9:544 | C |
| Yamane K, Ikeda T, Taniguchi R, Kita T, Kimura T, Horiuchi H. Characterization of the antiplatelet effect of aspirin at enrollment and after a 2-year follow-up in the real clinical setting in Japan. J Thromb Haemost 2011;9:85 | D |
| Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005;115:25–9 | D |
| Yong G, Rankin J, Ferguson L, Thom J, French J, Brieger D, et al. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. Am Heart J 2009;157:60–9 | C |
| Yoo JR, Kim SY, Kim KS, Joo S-J. Prevalence and clinical characteristics of aspirin resistance defined by impedance platelet aggregometry. Am J Cardiol 2012;109(Suppl. 1):13S | D |
| Zalewski J, Lech P, Durak M, Roslawiecka A, Gajos G, Undas A, et al. Platelet function in patients with ST-segment elevation myocardial infarction is associated with microvascular injury. Eur Heart J 2010;31:772 | D |
| Zawilska KM, Jamrozek-Jedlinska M, Duszynska M, Jedlinski I, Slomczynski M. Time-related changes of the sensitivity to anti-platelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention. J Thromb Haemost 2011;9:547–8 | D |
| Zhao YJ, Zhou LJ, Li WM, Liu PD, Chen YD, Song LY. [Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome.] Zhonghua Yi Xue Za Zhi 2008;88:2553–5 | C |
| Zhivoderov VM, Kondratchik SI. [Relation between disorders of lipid metabolism and the process of blood coagulation in myocardial infarct according to thrombelastographic data.] Ter Arkh 1975;47:68–72 | D |
| Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;121:982–4 | D |
| Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Hohlfeld T. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008;135:947–8 | D |
| Zoller H, Suss W, Gross W. [Thrombocytes, blood coagulation factors and fibrinolysis following aortocoronary venous bypass operation.] Vasa Suppl 1991;32:305–8 | D |
| Zurn CS, Geisler T, Paterok M, Gawaz M. [Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention.] Dtsch Med Wochenschr 2008;133:817–22 | C |
| Zytkiewicz M, Gielwanowska L, Wojtasinska E, Psuja P, Zawilska K. Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008;118:727–33 | D |
